



# What Is The Association Between Pedal Access Intervention And Radiologically Measured Wound Healing Progression In Diabetic Foot Ulcers? : A Systematic Review

<sup>1</sup> Haekal Mahargias, <sup>2</sup> Febrina Mayasari Gunawan, <sup>3</sup> Mutiara Amalia

<sup>1</sup> General Practitioner, Karubaga Regional General Hospital, Tolikara Regency, Papua Highlands, Indonesia

<sup>2</sup> Radiology Specialist, Metro Hospitals Cikupa General Hospital, Indonesia

<sup>3</sup> General Practitioner, Metro Hospitals Cikupa General Hospital, Indonesia

Corresponding Email : [haekalmahagias@yahoo.com](mailto:haekalmahagias@yahoo.com)

## Article History :

Received date : 2025/11/25

Revised date : 2025/12/07

Accepted date : 2026/01/12

Published date : 2026/02/23



**Copyright:** © 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

E-ISSN :

ISSN 3048-1368



P-ISSN

ISSN 3048-1376



## ABSTRACT

**Introduction:** Diabetic foot ulcers (DFUs) represent a severe complication of diabetes, with peripheral artery disease (PAD) being a major contributor to poor healing and limb loss. Pedal access interventions, which target the small arteries of the foot, have emerged as a key revascularization strategy. However, the specific association between these procedures and radiologically measured wound healing progression requires systematic evaluation. This systematic review aims to synthesize the existing evidence on the association between pedal access interventions and radiologically assessed wound healing outcomes in patients with DFUs.

**Methods:** A systematic review was conducted following a pre-defined protocol. We screened studies based on abstracts for inclusion criteria focusing on: (1) patients with diabetic foot ulcers, (2) pedal access interventions (angioplasty, stenting, bypass), (3) outcomes including radiologically measured wound healing, and (4) appropriate study designs (e.g., cohort studies, RCTs). Data were extracted on study characteristics, patient populations, intervention details, radiological assessment methods, wound healing outcomes, and the association between them.

**Results:** From the screening of a large body of literature, data were extracted from numerous studies, many of which were observational cohorts. The patient populations were predominantly older males with long-standing diabetes and severe PAD. Pedal access interventions primarily involved endovascular techniques, such as angioplasty of tibial and pedal arteries, with some studies focusing on angiosome-guided or pedal arch revascularization (PAR). Radiological assessment methods varied, including duplex ultrasound (e.g., pedal acceleration time [PAT]), digital subtraction angiography (e.g., pedal arch patency), and plain radiographs (e.g., MAC scores). The synthesized evidence demonstrates a strong and consistent association between successful pedal access intervention and improved wound healing. Key findings show that a **complete pedal arch (CPA) post-intervention** is significantly associated with higher healing rates (e.g., 93.3% vs. 52.6% for an absent arch,  $p=0.003$ ), shorter healing times (e.g., 3.5 vs. 5.7 months,  $p<0.001$ ), and superior limb salvage (e.g., 100% vs. 68.4% at 1-year,  $p<0.001$ ) (Troisi et al., 2018; Ismail et al., 2020). Similarly, **successful PAR** was associated with an 86.7% healing rate compared to 59.1% in unsuccessful cases ( $P=0.007$ ) and dramatically lower major

amputation rates (5.1% vs. 40.9%,  $p \leq 0.001$ ) (Shahat et al., 2024; Jung et al., 2019). Angiosome-targeted revascularization also demonstrated superior healing outcomes compared to indirect revascularization (HR 1.97; 95% CI, 1.34-2.90) (Khor & Price, 2017; Söderström et al., 2013). Furthermore, novel non-invasive markers like PAT showed strong predictive value for wound healing (Sommerset et al., 2020; Karmy-Jones et al., 2024).

**Discussion:** The findings robustly support the critical importance of restoring direct, pulsatile blood flow to the foot, specifically through the pedal arch and its branches, to facilitate DFU healing. The pedal arch acts as the crucial final vascular circuit, and its patency is a key determinant of healing and limb salvage. The discussion highlights that the quality of the revascularization outcome, particularly the establishment of a CPA, may be more important than the specific revascularization technique used. The integration of advanced radiological assessments like PAT offers a promising, non-invasive tool for patient selection and monitoring. Despite the strength of these associations, significant heterogeneity in study design, outcome measures, and radiological protocols exists, underscoring the need for more standardized approaches in future research.

**Conclusion:** There is a definitive and positive association between successful pedal access intervention and radiologically measured wound healing progression in diabetic foot ulcers. Achieving a complete pedal arch and successful pedal arch revascularization are powerful predictors of superior outcomes, including faster healing, higher healing rates, and reduced amputation risk. These findings advocate for revascularization strategies that prioritize

direct flow to the foot and the use of objective, non-invasive imaging to guide management.

**Keywords:** Diabetic Foot Ulcer, Peripheral Artery Disease, Revascularization, Pedal Arch, Angioplasty, Wound Healing, Amputation, Pedal Acceleration Time, Angiosome.

---

## INTRODUCTION

---

### Background

Diabetic foot ulcers (DFUs) are a devastating and common complication of diabetes mellitus, representing a leading cause of non-traumatic lower limb amputations worldwide (Prompers et al., 2008). The pathophysiology of DFUs is complex and multifactorial, but the presence of peripheral artery disease (PAD) significantly complicates the clinical picture and dramatically impairs healing (J. Brownrigg et al., 2015). In patients with diabetes, PAD is often more severe and distal, typically affecting the infrapopliteal (below-the-knee) and pedal (foot) arteries, a pattern that is less common in non-diabetic populations (Hinchliffe et al., 2016). This distal disease burden compromises blood flow to the foot, leading to ischemia, poor tissue oxygenation, and a severely impaired capacity for wound healing. The pedal arch, the arterial connection between the dorsalis pedis and lateral plantar arteries, forms the primary source of collateral circulation to the foot. Its integrity is therefore paramount for adequate tissue perfusion, especially in the presence of proximal arterial occlusions (Troisi et al., 2017).

Revascularization is the cornerstone of treatment for ischemic DFUs, with the primary goal of restoring pulsatile blood flow to the foot to create an environment conducive to healing (Forsythe et al., 2020). While surgical bypass has historically been the gold standard, endovascular techniques, such as percutaneous transluminal angioplasty (PTA) and stenting, have become the preferred first-line approach in many centers due to their minimally invasive nature and acceptable outcomes (Hinchliffe et al., 2012). These interventions have progressively moved more distally, leading to the concept of "pedal access" or "pedal artery intervention," which specifically targets the small-caliber arteries at the ankle and within the foot itself. The rationale is that merely restoring flow to a proximal tibial artery may be insufficient if the downstream pedal arch is diseased or occluded, a phenomenon known as "no flow to the foot" (Nakama et al., 2017).

### Research Gap

#### The International Journal of Medical Science and Health Research

Despite the widespread adoption of pedal access interventions, a critical gap exists in our understanding of their specific association with objective, radiologically measured wound healing progression. Many studies have focused on clinical outcomes like limb salvage or amputation rates, which, while crucial, are often the result of a composite of factors including wound care, infection control, and patient comorbidities. Furthermore, the assessment of wound healing has traditionally relied on clinical observation and planimetry, which can be subjective and lack precision in assessing deeper tissue recovery, such as bone healing or microvascular perfusion (R. Snyder et al., 2010). The emergence of advanced imaging modalities, such as high-frequency duplex ultrasound (e.g., to measure Pedal Acceleration Time [PAT]), 2D perfusion angiography, and MRI, allows for a more objective and quantitative evaluation of the biological effects of revascularization at the tissue level (Spiliopoulos et al., 2023; Troisi et al., 2021a). However, a systematic synthesis of the literature linking these specific radiological findings to healing outcomes following pedal access procedures is lacking. This review aims to consolidate the existing evidence to address this precise question.

### **Novelty of This Review**

This systematic review provides a novel contribution by focusing specifically on the *association* between an *intervention* (pedal access procedures) and a *specific outcome* (radiologically measured wound healing). By centering on radiological measures, we move beyond subjective clinical assessments and attempt to quantify the physiological impact of restoring foot-level perfusion. It synthesizes data on both the intervention's technical success and the subsequent biological response as captured by imaging, offering a more nuanced understanding of the causal pathway. Furthermore, it examines key concepts like the quality of the pedal arch, the role of angiosome-directed therapy, and the utility of novel imaging biomarkers in predicting and monitoring healing.

### **Research Question, Aims, and Hypotheses**

The primary research question for this systematic review is: "**What is the association between pedal access intervention and radiologically measured wound healing progression in diabetic foot ulcers?**"

The primary aim is to systematically review and synthesize the literature to determine the direction and strength of this association.

Secondary aims include:

1. To identify the most common and effective pedal access interventions.
2. To catalog the radiological methods used to assess wound healing and foot perfusion.
3. To evaluate the impact of pedal arch patency and angiosome-directed revascularization on healing outcomes.
4. To identify key confounding factors and study limitations in the existing evidence.

The hypothesis is that successful pedal access intervention, defined by radiological evidence of improved pedal perfusion (e.g., a complete pedal arch, reduced PAT, patent pedal vessels), is positively and significantly associated with accelerated and more complete wound healing in patients with DFUs.

### **Benefits of the Study**

The findings of this review will be of significant benefit to several stakeholders:

- **Clinicians (Vascular Surgeons, Interventional Radiologists, Podiatrists):** It will provide an evidence-based framework for decision-making, helping to select patients most likely to benefit from pedal access procedures and to set realistic expectations for healing.

- **Patients:** It will provide clearer information on the potential benefits of these interventions for their specific condition, particularly regarding the likelihood of wound healing and limb preservation.
- **Researchers:** It will identify key research gaps, highlight the need for standardized outcome measures, and inform the design of future prospective trials.
- **Healthcare Systems:** By clarifying the link between successful revascularization and healing, it supports the allocation of resources towards multidisciplinary teams and advanced imaging technologies to prevent costly and debilitating amputations.

---

## METHODS

---

### Protocol

The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines to ensure methodological rigor and accuracy. This approach was chosen to enhance the precision and reliability of the conclusions drawn from the investigation.

### Criteria for Eligibility

This systematic review aims to evaluate what is the association between pedal access intervention and radiologically measured wound healing progression in diabetic foot ulcers ?

### Screening

We screened in sources based on their abstracts that met these criteria:

- **Population - Diabetic Foot Ulcers:** Does the study include patients diagnosed with diabetes mellitus who have foot ulcers?
- **Intervention - Pedal Access Procedures:** Does the intervention involve pedal access procedures (angioplasty, stenting, bypass surgery, or other revascularization procedures targeting pedal vessels)?

- **Outcomes - Radiological Wound Healing Assessment:** Do the primary or secondary outcomes include radiologically assessed wound healing measures (wound size reduction, tissue perfusion, bone healing, or other imaging-based healing parameters)?
- **Study Design - Comparison Methods:** Does the study include a comparison group or pre-post intervention measurements?
- **Study Design - Appropriate Study Types:** Is the study design a randomized controlled trial, controlled clinical trial, cohort study, case-control study, systematic review, or meta-analysis?
- **Population Focus - Diabetic Etiology:** Does the study focus on diabetic foot ulcers rather than solely on acute limb ischemia or trauma-related wounds without diabetes?
- **Intervention Focus - Pedal Vessel Involvement:** Does the intervention include pedal vessel involvement rather than targeting only proximal vessels (iliac, femoral, popliteal) without pedal vessel involvement?
- **Study Quality and Type:** Is the study something other than a case report, case series with fewer than 10 patients, editorial, conference abstract, in vitro study, or animal study?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

### Search Strategy

The keywords used for this research based PICO :

Element	P (Population)	I (Intervention/Exposure)	C (Comparison/Context)	O (Outcome)
Keyword 1	Diabetic Foot Ulcers	Pedal Access Intervention	Comparison Groups	Wound Healing Progression
Keyword 2	Diabetes Mellitus	Revascularization	Indirect Revascularization	Radiological Assessment

<b>Keyword 3</b>	Peripheral Artery Disease	Angioplasty	Standard Care	Pedal Arch Patency
<b>Keyword 4</b>	Chronic Limb-Threatening Ischemia	Pedal Arch Intervention	Direct Revascularization	Limb Salvage

The Boolean MeSH keywords inputted on databases for this research are: ("Diabetic Foot Ulcers" OR "Diabetes Mellitus" OR "Peripheral Artery Disease" OR "Chronic Limb-Threatening Ischemia") AND ("Pedal Access Intervention" OR "Revascularization" OR "Angioplasty" OR "Pedal Arch Intervention") AND ("Comparison Groups" OR "Indirect Revascularization" OR "Standard Care" OR "Direct Revascularization") AND ("Wound Healing Progression" OR "Radiological Assessment" OR "Pedal Arch Patency" OR "Limb Salvage")

### Data extraction

- **Study Design:**

Extract study design type (RCT, cohort, case-control, cross-sectional, systematic review, etc.), sample size, setting (hospital, clinic, multi-center, etc.), and study duration. Include any design features that might affect the reliability of findings about pedal access intervention and wound healing associations.

- **Diabetic Population:**

Extract characteristics of diabetic foot ulcer patients, including:

- Demographics (age, gender, diabetes duration/type)
- Ulcer characteristics (location, size, depth, duration, Wagner/UT grade)
- Baseline peripheral artery disease status

- Comorbidities relevant to wound healing
- Exclusion criteria that might limit generalizability

- **Pedal Access Interventions:**

Extract details about pedal access interventions specifically targeting foot/ankle circulation for diabetic foot ulcer patients, including:

- Type of intervention (endovascular, surgical bypass, hybrid procedures, conservative management)
- Specific procedures performed (angioplasty, stenting, bypass grafts, etc.)
- Target vessels (pedal, ankle, below-knee arteries)
- Intervention success rates or technical outcomes
- Timing relative to ulcer presentation

- **Radiological Assessment:**

Extract methods used to radiologically measure wound healing progression in diabetic foot ulcers, including:

- Imaging modalities (duplex ultrasound, CT, MRI, plain radiographs, other)
- Specific measurements (pedal acceleration time, perfusion indices, vessel patency, wound area/depth)
- Assessment timing (baseline, post-intervention intervals, follow-up schedule)
- Who performed assessments and inter-observer reliability if reported

- **Wound Healing Outcomes:**

Extract wound healing progression outcomes as measured by radiological or clinical methods, including:

- Primary healing measures (time to complete healing, healing rates, wound closure percentages)

- Secondary outcomes (recurrence, amputation rates, reulceration)
- Quantitative results with statistical measures (means, medians, confidence intervals, p-values)
- Follow-up duration and completeness

- **Association Results:**

Extract findings specifically about the association between pedal access interventions and radiologically measured wound healing progression in diabetic foot ulcers, including:

- Statistical measures of association (odds ratios, hazard ratios, correlation coefficients, mean differences)
- Statistical significance levels and confidence intervals
- Adjusted vs unadjusted results
- Subgroup analyses if performed
- Direction and strength of association (positive, negative, neutral)

- **Confounding Factors:**

Extract variables that were measured, controlled for, or identified as potential confounders in the relationship between pedal access intervention and wound healing progression, including:

- Patient factors (age, diabetes control, comorbidities, medication use)
- Ulcer factors (size, depth, infection, location)
- Treatment factors (wound care protocols, adjunct therapies, antibiotics)
- Variables included in multivariate analyses
- Unmeasured confounders acknowledged by authors

- **Study Limitations:**

Extract methodological limitations and quality factors that might affect the validity of findings about pedal access intervention and wound healing associations, including:

- Sample size limitations or power calculations
- Selection bias, measurement bias, or confounding issues
- Loss to follow-up rates and reasons
- Blinding of outcome assessors
- Standardization of interventions and outcome measurements
- Author-acknowledged limitations relevant to the research question

**Table 1.** Article Search Strategy

Database	Keywords	Hits
Pubmed	<i>("Diabetic Foot Ulcers" OR "Diabetes Mellitus" OR "Peripheral Artery Disease" OR "Chronic Limb-Threatening Ischemia") AND ("Pedal Access Intervention" OR "Revascularization" OR "Angioplasty" OR "Pedal Arch Intervention") AND ("Comparison Groups" OR "Indirect Revascularization" OR "Standard Care" OR "Direct Revascularization") AND ("Wound Healing Progression" OR "Radiological Assessment" OR "Pedal Arch Patency" OR "Limb Salvage")</i>	28
Semantic Scholar	<i>("Diabetic Foot Ulcers" OR "Diabetes Mellitus" OR "Peripheral Artery Disease" OR "Chronic Limb-Threatening Ischemia") AND ("Pedal Access Intervention" OR "Revascularization" OR "Angioplasty" OR "Pedal Arch Intervention") AND ("Comparison Groups" OR "Indirect Revascularization" OR "Standard Care" OR "Direct Revascularization") AND ("Wound Healing Progression" OR "Radiological Assessment" OR "Pedal Arch Patency" OR "Limb Salvage")</i>	251
Springer	<i>("Diabetic Foot Ulcers" OR "Diabetes Mellitus" OR "Peripheral Artery Disease" OR "Chronic Limb-Threatening Ischemia") AND ("Pedal Access Intervention" OR "Revascularization" OR "Angioplasty" OR "Pedal Arch Intervention") AND ("Comparison Groups" OR "Indirect Revascularization" OR "Standard Care" OR "Direct Revascularization") AND ("Wound Healing Progression" OR "Radiological Assessment" OR "Pedal Arch Patency" OR "Limb Salvage")</i>	197
Google Scholar	<i>("Diabetic Foot Ulcers" OR "Diabetes Mellitus" OR "Peripheral Artery Disease" OR "Chronic Limb-Threatening Ischemia") AND ("Pedal Access Intervention" OR "Revascularization" OR "Angioplasty" OR "Pedal Arch Intervention") AND ("Comparison Groups" OR "Indirect Revascularization" OR "Standard Care" OR "Direct Revascularization") AND ("Wound Healing Progression" OR "Radiological Assessment" OR "Pedal Arch Patency" OR "Limb Salvage")</i>	937
Wiley Online Library	<i>("Diabetic Foot Ulcers" OR "Diabetes Mellitus" OR "Peripheral Artery Disease" OR "Chronic Limb-Threatening Ischemia") AND ("Pedal Access Intervention" OR "Revascularization" OR "Angioplasty" OR "Pedal Arch Intervention") AND ("Comparison Groups" OR "Indirect Revascularization" OR "Standard Care" OR "Direct Revascularization") AND ("Wound Healing Progression" OR "Radiological Assessment" OR "Pedal Arch Patency" OR "Limb Salvage")</i>	350




Figure 1. Article search flowchart

---

## RESULTS

---

### Study Characteristics

Citation	Sample Size	Study Duration
<b>N. Troisi et al., 2018</b>	137	1.5 years
<b>J. Apelqvist et al., 2011</b>	1151	22 years
<b>Rachael O. Forsythe et al., 2020</b>	>13,000 across 64 studies	Not specified
<b>Jennifer Skolnik et al., 2021</b>	99	10 years
<b>N. Troisi et al., 2017</b>	93	1.5 years
<b>S. Jacqueminet et al., 2005</b>	32	At least one year
<b>E. Saricilar et al., 2023</b>	17 studies	Not specified
<b>Jill Sommerset et al., 2020</b>	54 limbs	Not mentioned
<b>Andreia Pinelo et al., 2024</b>	117 limbs	1 year
<b>Shiping Ji et al., 2022</b>	215	Data from 2016-2020, 2-year follow-up
<b>Osama A. Ismail et al., 2020</b>	60	3 years
<b>M. Ghweeba et al., 2022</b>	63	30 months
<b>Chang Sik Shin et al., 2025</b>	85 patients (88 limbs)	5 years
<b>Ahmed Hossny et al., 2019</b>	60	1.5 years
<b>B. Y. C. Khor et al., 2017</b>	280	Not mentioned

Citation	Sample Size	Study Duration
<b>M. Söderström et al., 2013</b>	226 patients (250 legs)	At least 12 months
<b>Limi Lee et al., 2024</b>	150 patients (163 limbs)	Up to 2 years
<b>K. Dell et al., 2021</b>	19	4 to 6 weeks
<b>R. Hinchliffe et al., 2016</b>	13,434 across 64 studies	Includes studies from 1980-2018
<b>Riyad Karmy-Jones et al., 2024</b>	54	5 years
<b>K. Chae et al., 2016</b>	727 patients (881 feet)	Follow-up 1-68 months
<b>A. Caetano et al., 2020</b>	314	Mean follow-up ~2 years
<b>M. Fujii et al., 2021</b>	30	8 years
<b>N. Troisi et al., 2021</b>	153	1 year
<b>Mohammed Shahat et al., 2024</b>	120	2 years
<b>V. Alexandrescu et al., 2019</b>	167 patients (194 limbs)	~8 years, mean follow-up 10.9 months
<b>R. Hinchliffe et al., 2012</b>	Not specified	Search period 1980-2010
<b>Mohamed Fathy Abdelghaffar et al., 2023</b>	40	Not mentioned

Citation	Sample Size	Study Duration
V. Chuter et al., 2023	5190	Follow-up at least 6 months
G. Andros et al., 2004	Not mentioned	Not mentioned
K. Claesson et al., 2011	115 patients (135 limbs)	2 years, median follow-up 17 months
T. Elgzyri et al., 2014	478	Until healing or death
T. Nakama et al., 2017	257	Not mentioned
H. Jung et al., 2019	239	1-year follow-up
Michael Rouse et al., 2024	28 angiograms	~7 months
V. Alexandrescu et al., 2009	161 patients (176 limbs)	~5 years, mean follow-up 22.1 months
Danlan Pu et al., 2019	82	6 months
Ridho Sinaga et al., 2021	48	11 months
O. Galimov et al., 2021	36	Treatment in 2019-2020, 24-month follow-up
S. Spiliopoulos et al., 2023	28	At least 12 months
F. Álvaro-Afonso et al., 2024	28	At least 6 months

Citation	Sample Size	Study Duration
Tracy J. Cheun et al., 2024	1,768	12 years
B. Dong et al., 2022	50	~4.5 years
Jon C. Henry et al., 2016	130 limbs	Mean follow-up ~2 years
J. Vouillarmet et al., 2016	Not specified	Not specified
Thomas Collins et al., 2024	Not mentioned	Not mentioned
M. Sabry et al., 2023	42	Not mentioned
Rongzhi Wen et al., 2023	70	1.5 years
M. E. Yamany et al., 2020	30	1.5 years
Keisuke Miyake et al., 2024	117 limbs	4 years
B. Vijaynagar et al., 2019	248	2 years
M. N. Bouayed et al., 2019	903	11 years, follow-up 41 months
Pam Chen et al., 2024	Varies	Up to October 2022
J. Brownrigg et al., 2013	Not mentioned	Not mentioned
M. Doyle et al., 2020	310	1 year
Alexander T. Hong et al., 2025	178	12 months
N. Troisi et al., 2021a	24	6 months

Citation	Sample Size	Study Duration
<b>Fengjie Tang et al., 2023</b>	68	12 weeks
<b>Rushabh A Parekh et al., 2024</b>	50	24 months
<b>R. Jarosiková et al., 2025</b>	54	Follow-up at 3 and 6 months
<b>E. Iacopi et al., 2023</b>	89	1 year
<b>Mwidimi Ndosi et al., 2017</b>	299	12 months
<b>Hendri et al., 2023</b>	Not mentioned	Not mentioned
<b>Stephanie Mae Macfarlane et al., 2024</b>	120 patients (207 ulcers)	2 years
<b>P. Faries et al., 2004</b>	Not mentioned	Not mentioned
<b>Mohamed Elyamany et al., 2025</b>	41	Not mentioned
<b>H. Mohafez et al., 2018</b>	20	12 weeks
<b>Sijie Yang et al., 2024</b>	202	Not mentioned
<b>Andreia Pinelo et al., 2024a</b>	60 limbs	12-16 weeks after first evaluation
<b>Rachael O. Forsythe et al., 2016</b>	5890	Not specified
<b>Marta Carmena-Pantoja et al., 2021</b>	102	~3 years, 1-year follow-up
<b>K. Spanos et al., 2017</b>	103	12 months

Citation	Sample Size	Study Duration
<b>Odette Hart et al., 2024</b>	Not mentioned	Not mentioned
<b>P. Ince et al., 2007</b>	Not mentioned	Not mentioned
<b>Rachael O. Forsythe et al., 2020a</b>	~6800	Includes studies from 1980-2018
<b>K. Marmagkiolis et al., 2017</b>	881	Search period 2003-2016
<b>Nicole K. Cates et al., 2019</b>	284	Not mentioned
<b>M. Meloni et al., 2021</b>	196	~1.5 years
<b>A. Hartemann-Heurtier et al., 2002</b>	157	2 years
<b>C. Gazzaruso et al., 2020</b>	583	10 years
<b>Yan Chen et al., 2019</b>	273	Treatment from 2011-2017, 2-year follow-up
<b>Eduardo Silva et al., 2025</b>	88 patients (100 limbs)	Not mentioned
<b>B. Lin et al., 2020</b>	50	1 year
<b>R. Somayaji et al., 2017</b>	49	~1.5 years
<b>P. Normahani et al., 2020</b>	48 patients (50 limbs)	12 months
<b>Yingzhou Liu et al., 2023</b>	55,409	~9 years
<b>Sichun Zhao et al., 2024</b>	66	~1.5 years

Citation	Sample Size	Study Duration
<b>D. Lowry et al., 2018</b>	23	Monthly until healing
<b>Jason Zhang et al., 2024</b>	152	4 years
<b>Raffaele Grande et al., 2020</b>	2	Not mentioned
<b>Yan-Bin Wang et al., 2024</b>	62	2 years
<b>M. Doyle et al., 2020a</b>	310	Minimum 12 months follow-up
<b>N. Akhtar et al., 2020</b>	210	9 months
<b>García-Sáenz Mc et al., 2004</b>	Not mentioned	Not mentioned
<b>J. Brownrigg et al., 2015</b>	Not mentioned	Not mentioned
<b>A. Brechow et al., 2013</b>	736	8 years (2-year follow-up)
<b>Jason Chow et al., 2024</b>	136	4 years
<b>Junpeng Liu et al., 2024</b>	98	~2.5 years
<b>D. Margolis et al., 2002</b>	>31,000	At least 20 weeks
<b>F. Game et al., 2016</b>	30 articles	Not mentioned
<b>R. Snyder et al., 2009</b>	Not specified	Not specified
<b>L. Prompers et al., 2008</b>	1,232	1 year
<b>Pamela Chen et al., 2023</b>	Not applicable	Not applicable

Citation	Sample Size	Study Duration
S. H. Lu et al., 2017	279 patients (332 DFUs)	5 years
D. Margolis et al., 2005	Not mentioned	>10 years
P. Lazzarini et al., 2020	Not specified	Search period 2014-2018
T. Kwan et al., 2015	80	3 months
V. Chuter et al., 2023a	Not mentioned	Not mentioned
W. Bevan et al., 2008	19 patients (24 feet)	~6.5 years
R. Snyder et al., 2010	142 DFUs total	12 weeks
Jasper A Sung et al., 2020	119	6 months
N. Santamaria et al., 2004	93	12 months
R. Warriner et al., 2011	120	7 weeks (focus)
Seoyoung C. Kim et al., 2017	20	2 weeks of injections
S. Zimny et al., 2005	Not mentioned	10 weeks
L. Ribu et al., 2008	127	1 year
T. Elgyri et al., 2013	602	Until healing or death
Betiel K. Fesseha et al., 2018	270 participants (584 wounds)	4.7 years
J. Lindberg et al., 2021	61 wounds	Not mentioned

Citation	Sample Size	Study Duration
<b>Martin C. Robson et al., 2000</b>	160	20 weeks
<b>Hsi-An Yang et al., 2025</b>	1454	Not mentioned
<b>D. Wukich et al., 2014</b>	114	5 years
<b>V. E. Parks et al., 2020</b>	Not mentioned	Not mentioned
<b>J. Reekers et al., 2013</b>	Not mentioned	Not mentioned
<b>V. Venkatesan et al., 2023</b>	Not specified	Not specified
<b>B. Aliahmad et al., 2018</b>	26	4 weeks
<b>J. Reekers et al., 2016</b>	Not specified	Not specified
<b>A. MacDonald et al., 2019</b>	23	12 weeks
<b>N. Kontopodis et al., 2016</b>	72	24 months
<b>Scott J Edwards et al., 2023</b>	Not mentioned	Not mentioned
<b>H. Elghazaly et al., 2023</b>	123	12 months
<b>Aditya Dutta et al., 2021</b>	43 individuals (47 DFUs)	12 weeks
<b>Nantawan Koonalinthip et al., 2021</b>	35	At least 16 weeks
<b>O. Oncul et al., 2007</b>	66	At least 4 weeks
<b>Ivana Roth-Albin et al., 2017</b>	40	1 year
<b>Nila N. Sari et al., 2025</b>	Not specified	Not specified

Citation	Sample Size	Study Duration
S. Mehta et al., 2010	Not mentioned	Not mentioned
Patricia M González-Villacorta et al., 2025	Not mentioned	Not mentioned
C. Hicks et al., 2018	621 wounds	Not mentioned
S. Engberg et al., 2019	Not mentioned	Not mentioned
D. Armstrong et al., 2020	10	Up to 12 weeks
Dr. Madhuri Jain et al., 2022	200	Not specified
Lucia Bubulac et al., 2025	28	8 weeks
Olivia V. Waldman et al., 2020	92	~3.5 years, mean follow-up 4.7 months
Jacqueline N. McNulty et al., 2018	60	Average of 220 days
Yumika Nishio et al., 2022	253	~15 years
Rona Kartika et al., 2020	30	~9 months
Arthur C Yelland et al., 2022	27,030	~3.75 years
F. Game et al., 2020	Not mentioned	Not mentioned
Sebastián Flores-Escobar et al., 2025	30	12-week treatment
David A. Reiter et al., 2025	17	12 weeks post-MRI
J. A. Cheong et al., 2022	37	Not mentioned

Citation	Sample Size	Study Duration
<b>Bhavani Prasad Mahindrakar et al., 2023</b>	54	18 months
<b>Aroa Tardáguila-García et al., 2023</b>	116	4 years
<b>Jarrood M. Shapiro et al., 2011</b>	Not specified	Not specified
<b>Sooraj M Shah et al., 2019</b>	Not mentioned	Not mentioned
<b>Jiyong Ahn et al., 2025</b>	101 DFUs	~10 months
<b>Aroa Tardáguila-García et al., 2022</b>	115	1-year follow-up
<b>Jiyong Ahn et al., 2024</b>	101 DFUs	10 months
<b>A. Liakos et al., 2020</b>	Not mentioned	Not mentioned
<b>A. M. Mahon et al., 2017</b>	74	12 weeks
<b>T. Macioch et al., 2015</b>	120	6 months
<b>Sofija Pejkova et al., 2025</b>	20	At least 9 months
<b>Mariyam Iqbal et al., 2024</b>	300	10 months
<b>Hanan Ansari et al., 2025</b>	130	12 months
<b>N. Leone et al., 2025</b>	40	6 months
<b>Jessica M. Eager et al., 2025</b>	78 total (27 discovery, 51 validation)	12 weeks
<b>Ivan Jozic et al., 2024</b>	Not mentioned	4 weeks

Citation	Sample Size	Study Duration
<b>Максим Борисович Горобейко et al., 2014</b>	Not mentioned	Not mentioned
<b>Tawfik Abo Mera et al., 2019</b>	Not mentioned	Not mentioned
<b>Nasibeh Vatankhah et al., 2017</b>	101 patients (120 ulcers)	~3.5 years
<b>S. Brown et al., 2025</b>	300	Not mentioned
<b>Asmat Burhan et al., 2023</b>	127 total (68 intervention, 59 control)	8 weeks
<b>M. DeSanto et al., 2020</b>	Not specified	Not specified
<b>Stephanie P. Hao et al., 2020</b>	92	~3.75 years
<b>P. Tappia et al., 2021</b>	16	Up to 16 weeks
<b>Vishnu S. Ravidas et al., 2020</b>	105	18 months
<b>Takeshi Fukuda et al., 2019</b>	Not mentioned	Not mentioned
<b>Tze-Woei Tan et al., 2022</b>	51,362	Up to ~3 years
<b>Yan Mi et al., 2025</b>	60	4 years
<b>Kaitlyn K Rogers et al., 2023</b>	62	16 weeks
<b>Ivan Y. Luu et al., 2024</b>	16,905	6 years

### Patient Population and Ulcer Characteristics

The patient populations across the included studies consisted primarily of older adults with a mean or median age ranging from the mid-50s to mid-70s, with a consistent male predominance. Diabetes duration was often long, with mean durations reported from 10.5 to over 20 years. Ulcer characteristics were heterogeneous, with studies reporting on neuroischemic or ischemic ulcers of varying severity, commonly classified using the Wagner or University of Texas (UT) grading systems. Ulcer duration ranged from several weeks to chronic, non-healing states exceeding six months.

Baseline peripheral artery disease (PAD) was a universal inclusion criterion, with severity typically defined by low ankle-brachial index (ABI), toe pressures, or the presence of critical limb ischemia (CLI). Common comorbidities included hypertension, coronary artery disease, chronic kidney disease (including end-stage renal disease requiring dialysis), and smoking. Exclusion criteria frequently limited generalizability by omitting patients with severe, unsalvageable limb ischemia, active systemic infections, certain comorbidities like recent myocardial infarction or stroke, or a life expectancy of less than one year.

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
N. Troisi et al., 2018	137	74.7	Not mentioned	Rutherford class 5/6, TUC IID	Infrainguinal lesions, 57.7% in tibial artery	Insulin treatment

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>J. Apelqvist et al., 2011</b>	1151	75 (median)	Not mentioned	Neuroischemic/ischemic, Wagner grades	Severe PVD (toe pressure <45 mmHg or ankle pressure <80 mmHg)	Renal impairment, congestive heart failure
<b>Rachael O. Forsythe et al., 2020</b>	>13,000	Not mentioned	Not mentioned	Not mentioned	PAD	Not mentioned
<b>Jennifer Skolnik et al., 2021</b>	99	Not mentioned	Not mentioned	Not mentioned	PAD	Not mentioned
<b>N. Troisi et al., 2017</b>	93	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>S. Jacquemin et et al., 2005</b>	32	Not mentioned	Not mentioned	Severe ischemic ulcers	Severe limb ischemia	Not mentioned

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>E. Saricilar et al., 2023</b>	17 studies	Not mentioned	Not mentioned	Wagner grade 3-4	Atherosclerotic disease	Left ventricular dysfunction, ESRD, peripheral neuropathy
<b>Jill Sommerset et al., 2020</b>	54 limbs	Not mentioned	Not mentioned	Not mentioned	Isolated infrapopliteal occlusive disease, PAT > 225 ms	Not mentioned
<b>Andreia Pinelo et al., 2024</b>	114	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Shiping Ji et al., 2022</b>	215	Not mentioned	Not mentioned	Not mentioned	PAD requiring endovascular therapy	Not mentioned

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>Osama A. Ismail et al., 2020</b>	60	52-55	Not mentioned	Ulcers on toes, plantar area	Pedal arch classified as CPA, IPA, or APA	Smoking, hypertension
<b>M. Ghweeba et al., 2022</b>	63	66.7	93% insulin-dependent	Rutherford class 5/6	Pedal arch defects (CPA, IPA, APA)	Smoking, hypertension, hypercholesterolemia
<b>Chang Sik Shin et al., 2025</b>	85	Mentioned	Not mentioned	Wagner, UT, and Wifl grades	Not mentioned	Comorbidities explored
<b>Ahmed Hossny et al., 2019</b>	60	63.85	Not mentioned	Ischemic ulcer/gangrene	Critical lower limb ischemia	Smoking, hypertension, hyperlipidemia, IHD
<b>B. Y. C. Khor et al., 2017</b>	280	Not mentioned	Not mentioned	Not mentioned	Critical limb ischaemia	Diabetes

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>M. Söderström et al., 2013</b>	226	Not mentioned	Not mentioned	Not mentioned	Infrapopliteal disease	Not mentioned
<b>Limi Lee et al., 2024</b>	150	Not mentioned	Not mentioned	Tissue loss	Not mentioned	End-stage renal disease
<b>K. Dell et al., 2021</b>	19	Not mentioned	Not mentioned	Not mentioned	Medial arterial calcification	Osteomyelitis
<b>R. Hinchliffe et al., 2016</b>	13,434	71 (median)	Not mentioned	Not mentioned	Multi-level distal disease	CAD, CVA, ESRD
<b>Riyad Karmy-Jones et al., 2024</b>	54	Not mentioned	Not mentioned	Toe or heel wound	Diffuse infrageniculate disease	Ongoing smoking, dialysis
<b>K. Chae et al., 2016</b>	727	Not mentioned	Not mentioned	Ischemic ulcers	PAD in up to 50%	PAD

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
A. Caetano et al., 2020	314	Not mentioned	Not mentioned	Not mentioned	PAD requiring revascularization	Prior stroke, dialysis, CAD
M. Fujii et al., 2021	30	Not mentioned	Not mentioned	Wound grade 0-3	Implied by skin perfusion pressure	Hemodialysis
N. Troisi et al., 2021	153	Not mentioned	Not mentioned	Not mentioned	Pedal arch classified as CPA, IPA, APA	Smoking, chronic renal failure, CAD
Mohammed Shahat et al., 2024	120	Not mentioned	Not mentioned	WIFI stages 2-4	CLTI, infrainguinal disease	Not mentioned
V. Alexandrescu et al., 2019	167	72.8	Not mentioned	Wagner 2-4, Rutherford 5	Chronic limb-threatening ischemia	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>R. Hinchliffe et al., 2012</b>	Not specified	Not mentioned	Not mentioned	Not mentioned	PAD in up to 50%	Not mentioned
<b>Mohamed Fathy Abdelghaffar et al., 2023</b>	40	Not mentioned	Not mentioned	Multiple tibial and pedal arch disease	CLI	Diabetes, hypertension, renal insufficiency, obesity
<b>V. Chuter et al., 2023</b>	5190	Not mentioned	Not mentioned	Tissue loss in >80%	Diagnosed PAD	Cardiovascular morbidity
<b>G. Andros et al., 2004</b>	Not specified	Not mentioned	Not mentioned	Not mentioned	Arterial occlusive disease	Hemodialysis
<b>K. Claesson et al., 2011</b>	115	73 (median)	Not mentioned	Wagner grade $\geq 3$	Concomitant PAD	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
T. Elgyri et al., 2014	478	74	Not mentioned	Wagner grade <3	Toe pressure <45 mmHg or ankle pressure <80 mmHg	Intermittent claudication , peripheral edema
T. Nakama et al., 2017	257	Not mentioned	Not mentioned	UT grade $\geq 2$	Infrapopliteal and pedal artery disease	Nonambulatory status, daily hemodialysis
H. Jung et al., 2019	239	Not mentioned	Not mentioned	Chronic ischemic wound	Infrapopliteal artery disease	Gangrene, elevated CRP
Michael Rouse et al., 2024	Not specified	Not mentioned	Not mentioned	Nonhealing wounds (67.9%)	Not mentioned	Hypertension, HLD, diabetes, CAD, tobacco use

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>V. Alexandrescu et al., 2009</b>	161	>70 years	Not mentioned	Ischemic wounds, tissue defects >3 cm	Not mentioned	ESRD, osteomyelitis, neuropathy, cardiac failure
<b>Danlan Pu et al., 2019</b>	82	Not mentioned	Not mentioned	Not mentioned	Lower extremity arterial disease (LEAD)	Not mentioned
<b>Ridho Sinaga et al., 2021</b>	48	62 (median)	Not mentioned	Size >3 cm <sup>2</sup> , depth grade 3	PAD (81.3%), CLI (18.2%)	Anemia, high urea/creatinine, leukocytosis
<b>O. Galimov et al., 2021</b>	36	Not mentioned	Type 2 diabetes	Purulent necrotic lesions	Not mentioned	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
S. Spiliopoulos et al., 2023	28	Not mentioned	Not mentioned	Wound class $\geq 1$	CLTI	Not mentioned
F. Álvaro-Afonso et al., 2024	28	Not specified	96% Type 2	Ischemic or neuroischemic, UT grades IC-III D	PAD requiring revascularization	Hypertension, HLD, neuropathy, cardiopathy
Tracy J. Cheun et al., 2024	1,768	67	Not mentioned	WIFI grade 3 and 4	CLTI, Tibial/pedal disease	Not mentioned
B. Dong et al., 2022	50	67.74	Not mentioned	Wagner grade mentioned	Femoral-popliteal and inferior knee artery occlusion	Not mentioned
Jon C. Henry et al., 2016	122 limbs	Not mentioned	Not mentioned	Rutherford class 5 and 6	Infrapopliteal disease	Malignant disease, warfarin use

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>J. Vouillarmet et al., 2016</b>	Not specified	Not mentioned	Not mentioned	Not mentioned	PAD, CLI	Microcirculation disorders, abnormal angiogenesis
<b>Thomas Collins et al., 2024</b>	Not specified	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned
<b>M. Sabry et al., 2023</b>	42	Not mentioned	Not mentioned	Not mentioned	Infrapopliteal and pedal artery disease	Not mentioned
<b>Rongzhi Wen et al., 2023</b>	70	55.21	13.94 (mean)	Wagner grade 2-4	ABI <0.9	Not mentioned
<b>M. E. Yamany et al., 2020</b>	30	18-80	90% diabetic	Texas D1-D3	Critical limb ischemia	Hypertension, dyslipidemia

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>Keisuke Miyake et al., 2024</b>	117 limbs	Not mentioned	Not mentioned	Wifi classification	CLTI	Not mentioned
<b>B. Vijaynagar et al., 2019</b>	248	Not mentioned	Not mentioned	Not mentioned	Vascular input needed (62%)	Not mentioned
<b>M. N. Bouayed et al., 2019</b>	903	61	Not mentioned	Wagner grades 2, 3, 4	Severe ischemia	Not mentioned
<b>Pam Chen et al., 2024</b>	Not specified	Not mentioned	Not mentioned	Wagner 1 or 2	Not mentioned	No significant comorbidities
<b>J. Brownrigg et al., 2013</b>	Not specified	Not mentioned	Not mentioned	Not mentioned	PAD	Not mentioned
<b>M. Doyle et al., 2020</b>	310	Not mentioned	Not mentioned	Not mentioned	PAD	Diabetes, ESRD

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
Alexander T. Hong et al., 2025	178	55.4	Not mentioned	Not mentioned	PAD (35%)	PAD, ESRD (13%)
N. Troisi et al., 2021a	24	Not mentioned	Not mentioned	Foot wounds	Multilevel CLTI	Not mentioned
Fengjie Tang et al., 2023	68	63	Not mentioned	Neuropathic, located at digits	Not mentioned	Not mentioned
Rushabh A Parekh et al., 2024	50	50.72	Not mentioned	DFU	ABPI <0.9 (76%), TBI <0.65 (32%)	Smoking (74%), intermittent claudication (42%)
R. Jarosiková et al., 2025	54	Age associated with MAC/SAD score	Not mentioned	DFU	PAD (GLASS, Graziani systems)	Not mentioned
E. Iacopi et al., 2023	89	68.8 / 70.4	19.6 / 18.8	Osteomyelitis	65.2% / 67.4% PAD	CKD, IHD

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>Mwidimi Ndotsi et al., 2017</b>	299	64	Not mentioned	PEDIS and Wagner classification	PEDIS perfusion grade	Not mentioned
<b>Hendri et al., 2023</b>	Not specified	Not mentioned	Not mentioned	WIFI score used	PAD	Not mentioned
<b>Stephanie Mae Macfarlane et al., 2024</b>	120	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned
<b>P. Faries et al., 2004</b>	Not specified	Not mentioned	Not mentioned	DFU	Peripheral arterial occlusive disease	Neuropathy
<b>Mohamed Elyamany et al., 2025</b>	41	>18	Not mentioned	Rest pain or tissue loss	CLTI	Not mentioned
<b>H. Mohafez et al., 2018</b>	20	55.5	10.5	Wagner grade 1-3	PAD (15 patients)	Hypertension, HLD, CKD

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>Sijie Yang et al., 2024</b>	202	Not mentioned	Not mentioned	Wagner's grading	Not mentioned	Not mentioned
<b>Andreia Pinelo et al., 2024a</b>	Not specified	Not mentioned	Not mentioned	Ischemic foot ulcers	Not mentioned	Not mentioned
<b>Rachael O. Forsythe et al., 2016</b>	5890	61-76	Not mentioned	Wagner grade $\geq 3$ (16-61%)	ABI $< 0.9$	ESRF, infection
<b>Marta Carmena-Pantoja et al., 2021</b>	102	Not mentioned	Not mentioned	DFU complicated by osteomyelitis	Presence of RAC and mild/moderate PAD	Not mentioned
<b>K. Spanos et al., 2017</b>	103	69.7	17.7	UT grade 1	PAD (53.4%)	HT, CAD
<b>Odette Hart et al., 2024</b>	Not specified	Not mentioned	Not mentioned	Ulceration and Gangrene	Not mentioned	Not mentioned
<b>P. Ince et al., 2007</b>	Not specified	Not mentioned	Not mentioned	Foot lesions	Not mentioned	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>Rachael O. Forsythe et al., 2020a</b>	~6800	58-76	Not mentioned	Not mentioned	PAD	Impaired perfusion, infection
<b>K. Marmagkoulis et al., 2017</b>	881	Not mentioned	Not mentioned	Not mentioned	CLI (68.4%)	Not mentioned
<b>Nicole K. Cates et al., 2019</b>	284	Not mentioned	Not mentioned	Ulceration and/or acute infection	PAD (59 patients)	Not mentioned
<b>M. Meloni et al., 2021</b>	196	70	18	Complicated/severely complicated ulcers	Ischemic (55.5%)	HT, HLD, IHD, CVA, ESRD
<b>A. Hartemann-Heurtier et al., 2002</b>	118	Not mentioned	Not mentioned	High-grade ulcers	Arterial disease	Renal replacement therapy

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
C. Gazzaruso et al., 2020	583	Not mentioned	Type 2 diabetes	DFU	Markers of PAD	Renal impairment, cardiovascular disease, osteomyelitis
Yan Chen et al., 2019	273	60-61	Not mentioned	UT Grade 2B to 3D	Assessed by CT angiography	Not mentioned
Eduardo Silva et al., 2025	88	75 (median)	Not mentioned	Lower limb wounds	PAD	Not mentioned
B. Lin et al., 2020	50	Group C older	Not mentioned	Group C had more severe wounds	Group A (no PAD), B (PAD w/o angioplasty), C (PAD w/ angioplasty)	History of amputation (more in Group C)

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>R. Somayaji et al., 2017</b>	49	64.2	Not mentioned	Median duration 26 weeks, unspecified etiology	Normal Doppler in 22.5%	HTN, dyslipidemia, PVD
<b>P. Normahani et al., 2020</b>	48	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Yingzhou Liu et al., 2023</b>	55,409	21-89	Not mentioned	Early stage, osteomyelitis, or gangrene	PVD listed as a comorbidity	Eye disease, heart disease, MI, PVD, renal disease, stroke
<b>Sichun Zhao et al., 2024</b>	66	Not mentioned	Not mentioned	Wagner grade 3 and 4	Not mentioned	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
D. Lowry et al., 2018	23	Not mentioned	Not mentioned	Foot ulceration	G1 (significant PAD), G2 (no significant PAD)	Not mentioned
Jason Zhang et al., 2024	152	58.8	Not mentioned	Size 8.27 cm <sup>2</sup> , depth 0.61 cm	PAD (26.3%), ABI 1.12	PAD
Raffaele Grande et al., 2020	2	73 & 80	Not mentioned	Lower limb ulcers	Advanced CLI	HTN, CKD, dyslipidemia
Yan-Bin Wang et al., 2024	62	≥ 18	Type 1 or 2	Wagner grade ≥2	Not mentioned	Not mentioned
M. Doyle et al., 2020a	310	Not mentioned	Not mentioned	Not mentioned	PAD requiring revascularization	Not mentioned
N. Akhtar et al., 2020	210	~46	10.17 / 10.56	Grade II, size ~5 cm <sup>2</sup>	Not mentioned	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>García-Sáenz Mc et al., 2004</b>	Not specified	Older patients	Type 2 diabetes	Not mentioned	Not mentioned	Not mentioned
<b>J. Brownrigg et al., 2015</b>	Not specified	Not mentioned	Not mentioned	Not mentioned	Co-existing PAD in ~50%	Infection, oedema, neuropathy
<b>A. Brechow et al., 2013</b>	736	66.3	15.8	Wagner 2-4, UT stage D	93.7% with PAD (various severity)	Nephropathy, hypertension, smoking
<b>Jason Chow et al., 2024</b>	136	Similar	Not mentioned	Forefoot, midfoot, hindfoot ulcers	Not mentioned	Peripheral neuropathy
<b>Junpeng Liu et al., 2024</b>	98	63.66	20.22	Wagner grade $\geq$ II	Patent popliteal and SFA	Hypertension (76.53%), Coronary heart disease (30.61%)

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>D. Margolis et al., 2002</b>	>31,000	Not mentioned	Not mentioned	Wound size, duration, grade evaluated	Not mentioned	Not mentioned
<b>F. Game et al., 2016</b>	30 articles	≥ 18	Type 1 or 2	Chronic foot ulcers	Not mentioned	Not mentioned
<b>R. Snyder et al., 2009</b>	Not specified	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned
<b>L. Prompers et al., 2008</b>	1,232	64.7	69.8% >10 years	Plantar (48.2%), deep (43.8%)	PAD (47.5%)	Heart failure, ESRD, neurological disorder
<b>Pamela Chen et al., 2023</b>	Not applicable	Not mentioned	Not mentioned	Chronic DFU	Not mentioned	Not mentioned
<b>S. H. Lu et al., 2017</b>	279	61.5	Not mentioned	Forefoot (82.5%)	Not mentioned	Not mentioned

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>D. Margolis et al., 2005</b>	Not specified	Not mentioned	Not mentioned	Neuropathic foot ulcer	Not mentioned	Not mentioned
<b>P. Lazzarini et al., 2020</b>	Not specified	Not specified	Not specified	Neuropathic plantar forefoot and midfoot ulcers	PAD	Peripheral neuropathy
<b>T. Kwan et al., 2015</b>	80	Not mentioned	Not mentioned	Not mentioned	Symptomatic PAD	Not mentioned
<b>V. Chuter et al., 2023a</b>	Not specified	Not mentioned	Not mentioned	DFU or gangrene	PAD	Not mentioned
<b>W. Bevan et al., 2008</b>	19	54	20 (median)	Midfoot callus/ulceration	Pedal pulses present	Not mentioned
<b>R. Snyder et al., 2010</b>	142 DFUs	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned
<b>Jasper A Sung et al., 2020</b>	119	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Active cigarette smokers

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>N. Santamaria et al., 2004</b>	93	Not mentioned	Not mentioned	Chronic leg and foot ulcers	Not mentioned	High levels of comorbidity
<b>R. Warriner et al., 2011</b>	120	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned
<b>Seoyoung C. Kim et al., 2017</b>	20	62 / 64	Type 2 diabetes	Wagner grade 1-4	ABI > 0.8	Not mentioned
<b>S. Zimny et al., 2005</b>	Not specified	Not mentioned	Not mentioned	Neuropathic ulcers, area 96.9 mm <sup>2</sup>	Not mentioned	Not mentioned
<b>L. Ribu et al., 2008</b>	127	Not mentioned	Type 1 or 2	Not mentioned	Not mentioned	Not mentioned
<b>T. Elgzyri et al., 2013</b>	602	76 (median)	Not mentioned	Ischemic foot ulcer	Toe pressure <45 mmHg or ankle pressure <80 mmHg	Rest pain, renal impairment, IHD, CVA

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>Betiel K. Fesseha et al., 2018</b>	270	Middle-aged	Long duration	Wifi stage	PVD	Advanced diabetes complications, poor glycemic control, smoking
<b>J. Lindberg et al., 2021</b>	61 wounds	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Martin C. Robson et al., 2000</b>	160	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Hsi-An Yang et al., 2025</b>	1454	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
D. Wukich et al., 2014	114	59	Mostly Type 2	Midfoot ulcers	No difference in prevalence	Active infection, high Michigan Neuropathy Screening Index
V. E. Parks et al., 2020	Not specified	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned
J. Reekers et al., 2013	Not specified	Not mentioned	Not mentioned	DF disease	PAD	Not mentioned
V. Venkatesan et al., 2023	Not specified	Not mentioned	Not mentioned	Foot ulcers	Peripheral vascular disease	Pedal neuropathy, perfusion disturbances

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>B. Aliahmad et al., 2018</b>	26	62 (median)	20 (median)	Plantar neuropathic DFU	PAD (52%)	Retinopathy, hypertension, dyslipidemia
<b>J. Reekers et al., 2016</b>	Not specified	Not mentioned	Not mentioned	Arterial diabetic foot disease	PAD	Not mentioned
<b>A. MacDonald et al., 2019</b>	23	52.08-59.9	Not mentioned	Wagner grade (commonly 3)	ABI > 0.75	Charlson Comorbidity Index 3.08-4.82
<b>N. Kontopodis et al., 2016</b>	72	Not mentioned	Not mentioned	Not mentioned	Group A (Fontaine I-IIb), Group B (Fontaine III-IV)	Not mentioned
<b>Scott J Edwards et al., 2023</b>	Not specified	Type-2 diabetes	Not mentioned	DFU	Not mentioned	Not mentioned

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>H. Elghazaly et al., 2023</b>	123	Not mentioned	Not mentioned	DFU	PAD	Not mentioned
<b>Aditya Dutta et al., 2021</b>	43	Not mentioned	Not mentioned	Neuropathic DFU, area 9.87 cm <sup>2</sup>	Not mentioned	Poorly controlled diabetes (HbA1c >9%)
<b>Nantawan Koonalinthip et al., 2021</b>	35	Not mentioned	Not mentioned	DFU and pre-ulcerative lesions	Not mentioned	Not mentioned
<b>O. Oncul et al., 2007</b>	38	Not mentioned	Not mentioned	Diabetic foot infection	Not mentioned	Not mentioned
<b>Ivana Roth-Albin et al., 2017</b>	40	Not mentioned	Not mentioned	Chronic ulcers, size >1 cm <sup>2</sup>	Not mentioned	Not mentioned
<b>Nila N. Sari et al., 2025</b>	Not specified	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>S. Mehta et al., 2010</b>	Not specified	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Patricia M González-Villacorta et al., 2025</b>	Not specified	Not mentioned	Not mentioned	DFU	PAD	Not mentioned
<b>C. Hicks et al., 2018</b>	621 wounds	Not mentioned	Not mentioned	Worse wound stage, larger area	PAD	Partially dependent functional status
<b>S. Engberg et al., 2019</b>	Not specified	Not mentioned	Not mentioned	Neuropathic, neuro-ischaemic, or critically ischaemic	Not mentioned	Not mentioned
<b>D. Armstrong et al., 2020</b>	10	Not mentioned	Not mentioned	Refractory wounds	Not mentioned	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>Dr. Madhuri Jain et al., 2022</b>	200	54.03	Not mentioned	PEDIS score used	PVD (22 patients)	Moderate anaemia, end organ damage
<b>Lucia Bubulac et al., 2025</b>	28	30-80	Type 1 or 2, >5 years	Meggitt-Wagner grades 2-4, size > 4 cm <sup>2</sup>	Distal pulse present	Neuropathy
<b>Olivia V. Waldman et al., 2020</b>	92	62.2	Not mentioned	Wagner score 2.92	Not mentioned	Chronic renal failure (23.9%)
<b>Jacqueline N. McNulty et al., 2018</b>	60	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Glycemic control evaluated
<b>Yumika Nishio et al., 2022</b>	253	Not mentioned	Not mentioned	Heel pressure ulcer	PAD (73.5%)	Not mentioned
<b>Rona Kartika et al., 2020</b>	30	Not mentioned	Not mentioned	Wagner-2, size < 40 cm <sup>2</sup>	Not mentioned	Not mentioned

<b>Citation</b>	<b>Sample Size</b>	<b>Mean Age (years)</b>	<b>Diabetes Duration (years)</b>	<b>Ulcer Grade/Classification</b>	<b>Baseline PAD Status</b>	<b>Key Comorbidities</b>
<b>Arthur C Yelland et al., 2022</b>	27,030	≥ 18	Not mentioned	Location, size, depth evaluated	Evidence of ischaemia	Kidney disease, MI, heart failure
<b>F. Game et al., 2020</b>	Not specified	Not mentioned	Not mentioned	DFU	PAD	Not mentioned
<b>Sebastián Flores-Escobar et al., 2025</b>	30	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>David A. Reiter et al., 2025</b>	17	Not mentioned	Not mentioned	Plantar forefoot ulcers, duration ≥ 30 days	Not mentioned	Not mentioned
<b>J. A. Cheong et al., 2022</b>	37	Not mentioned	Not mentioned	DFU	PAD defined by ABI	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>Bhavani Prasad Mahindrakar et al., 2023</b>	54	55	Not mentioned	Uninfected DFU	Not mentioned	Not mentioned
<b>Aroa Tardáguila-García et al., 2023</b>	116	62.9	17.5	Forefoot (92.2%), duration 15.7 weeks	PAD (41.4%)	Neuropathy
<b>Jarrold M. Shapiro et al., 2011</b>	Not specified	Not mentioned	Not mentioned	DFU	Infrapopliteal macrocirculatory disease	Not mentioned
<b>Sooraj M Shah et al., 2019</b>	Not specified	Not mentioned	Not mentioned	Not mentioned	Infrainguinal PAD	Not mentioned
<b>Jiyong Ahn et al., 2025</b>	101 DFUs	Not mentioned	Not mentioned	Wagner 3 or 4	Not mentioned	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>Aroa Tardáguila-García et al., 2022</b>	115	Not mentioned	Not mentioned	DFO	Not mentioned	Not mentioned
<b>Jiyong Ahn et al., 2024</b>	101 DFUs	Not mentioned	Not mentioned	Wagner 3 and 4	Patent peroneal artery mentioned	Not mentioned
<b>A. Liakos et al., 2020</b>	Not specified	Not mentioned	Not mentioned	Refractory DFU	Not mentioned	Not mentioned
<b>A. M. Mahon et al., 2017</b>	74	67	Not mentioned	Larger wound area	Ischaemia	Infection
<b>T. Macioch et al., 2015</b>	120	61.1	Not mentioned	Size 5.6 cm <sup>2</sup> (initial)	Not mentioned	Not mentioned
<b>Sofija Pejkoval et al., 2025</b>	20	Not mentioned	Not mentioned	Duration 17.1 months, size 10.49 cm <sup>2</sup>	Not mentioned	Good glycemic control

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>Mariyam Iqbal et al., 2024</b>	300	61 / 68	Not mentioned	Wagner 2-4, midfoot/forefoot ulcers	PAD (60% / 68%)	Coronary artery disease
<b>Hanan Ansari et al., 2025</b>	130	58.7	≥ 5 years	Wagner grade ≥2	Not mentioned	Hypertension, dyslipidemia, renal disease
<b>N. Leone et al., 2025</b>	40	Not mentioned	Not mentioned	DFU undergoing minor amputation	Not mentioned	Haemodialysis, opioid use
<b>Jessica M. Eager et al., 2025</b>	78	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned
<b>Ivan Jozic et al., 2024</b>	Not specified	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>Максим Борисович Горобейко et al., 2014</b>	Not specified	Not mentioned	Not mentioned	DFU	Pedal ischemia (PtcO2 measured)	Not mentioned
<b>Tawfik Abo Mera et al., 2019</b>	Not specified	Not mentioned	Not mentioned	Diabetic foot lesions	Vascularity assessed	Not mentioned
<b>Nasibeh Vatankhah et al., 2017</b>	101	59.4	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>S. Brown et al., 2025</b>	300	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned
<b>Asmat Burhan et al., 2023</b>	127	>18	Not mentioned	DFU	PAD	Not mentioned
<b>M. DeSanto et al., 2020</b>	Not specified	Not mentioned	Not mentioned	DFU	Not mentioned	Not mentioned
<b>Stephanie P. Hao et al., 2020</b>	92	60.5	Not mentioned	DFU	Not mentioned	Not mentioned

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
<b>P. Tappia et al., 2021</b>	16	59.9	94% diabetic	Foot ulcer present	Assessed by ABI	ESRD (63%), below-knee amputation (38%)
<b>Vishnu S. Ravidas et al., 2020</b>	105	58.1-63.8	Not mentioned	Wagner class 1-5	Mean ABPI 0.7	Infection, neuropathy, poor glycemic control
<b>Takeshi Fukuda et al., 2019</b>	Not specified	Not mentioned	Not mentioned	Diabetic pedal disease	Not mentioned	Not mentioned
<b>Tze-Woei Tan et al., 2022</b>	51,362	≥ 40	Not mentioned	DFU	PAD (49.5% control, 64.2% intervention )	ESRD, various comorbidities via CCI

Citation	Sample Size	Mean Age (years)	Diabetes Duration (years)	Ulcer Grade/Classification	Baseline PAD Status	Key Comorbidities
Yan Mi et al., 2025	60	Not specified	Not mentioned	Wagner grade 3-4, duration >4 weeks	Not mentioned	Stable comorbidities, independent mobility
Kaitlyn K Rogers et al., 2023	62	Not specified	Not mentioned	DFU	PAD	Renal failure, prior amputation
Ivan Y. Luu et al., 2024	16,905	20-69	Not mentioned	DFU	PAD	COPD, CVD, CKD, CHF, CAD, HTN, obesity, depression

### Pedal Access Intervention Approaches

The interventions employed across studies to improve foot-level circulation in patients with diabetic foot ulcers primarily involved endovascular procedures, with surgical bypass and hybrid approaches also utilized. Endovascular techniques were the most common first-line strategy, including percutaneous transluminal angioplasty (PTA) with or without stenting. The target vessels for these interventions were predominantly below-the-knee arteries, including tibial, ankle, and pedal arteries.

Several studies focused on the concept of angiosome-guided revascularization, comparing direct revascularization (DR) of the artery supplying the ulcerated area with indirect revascularization (IR) through collateral vessels. The patency of the pedal arch emerged as a critical factor, with interventions specifically aimed at pedal arch revascularization (PAR). Technical success rates for endovascular procedures were reported in a wide range, from approximately 61% to over 90%. The timing of interventions varied, with some studies implementing them as a first-line approach upon ulcer presentation, while others noted delays of several weeks post-referral.

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>N. Troisi et al., 2018</b>	Endovascular	Tibial arteries	87.6%	Angioplasty	Not detailed
<b>J. Apelqvist et al., 2011</b>	Endovascular (PTA), surgical bypass	Crural arteries	OR for healing: PTA 1.77, surgery 2.05	PTA, distal reconstructive surgery	Not specified
<b>Rachael O. Forsythe et al., 2020</b>	Endovascular and open surgery	Angiosome-related vessels	Not specified	Not mentioned	Not explicit
<b>Jennifer Skolnik et al., 2021</b>	Endovascular	Infrageniculate vessels	MALE in 50% at 1 year	Infrageniculate angioplasty	After ulcer presentation

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>N. Troisi et al., 2017</b>	Endovascular revascularization	Below-the-knee vessels	CPA group had better outcomes	Not specified	Healing evaluated at 3 months
<b>S. Jacqueminet et al., 2005</b>	Endovascular (PTA)	Pedal vessels	52% clinically successful	Angioplasty	First-line procedure
<b>E. Saricilar et al., 2023</b>	Endovascular	Below-knee arteries	60.9% to 84.7%	Angioplasty	After ulcer presentation
<b>Jill Sommerset et al., 2020</b>	Angiographic interventions	Tibial arteries	Associated with PAT values	Not specified	Not mentioned
<b>Andreia Pinelo et al., 2024</b>	Endovascular surgery	Pedal or below-knee arteries	Not mentioned	Not mentioned	Not mentioned
<b>Shiping Ji et al., 2022</b>	Endovascular therapy	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Osama A. Ismail et al., 2020</b>	Endovascular	Pedal arch	68.3%	Guidewire crossing, balloon dilatation	Part of management for CLI

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>M. Ghweeba et al., 2022</b>	Endovascular	Pedal arch and related vessels	High healing and limb preservation rates	Angioplasty with guidewire and balloon	Not mentioned
<b>Chang Sik Shin et al., 2025</b>	Endovascular (EVT)	Below-the-knee arteries	64.5% wound healing at 12 months	Infra-popliteal EVT	Not explicit
<b>Ahmed Hossny et al., 2019</b>	Endovascular (infrapopliteal angioplasty)	AT, PT, peroneal arteries	Healing rates varied by approach (43-94%)	Angioplasty	Follow-up post-intervention
<b>B. Y. C. Khor et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>M. Söderström et al., 2013</b>	Endovascular	Below-knee arteries	72% healing rate (direct) vs 45% (indirect)	Infrapopliteal PTA	After ulcer presentation
<b>Limi Lee et al., 2024</b>	Endovascular (proximal arterial inflow revascularization)	Pedal arch	24.1% increase in complete pedal arch patency	Not specified	After ulcer presentation

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>K. Dell et al., 2021</b>	Endovascular, surgical bypass	Pedal arteries	High healing rates (5/6 and 2/2)	Not specified	4-week follow-up
<b>R. Hinchliffe et al., 2016</b>	Endovascular, surgical bypass	Pedal, ankle, below-knee arteries	Median 1-year limb salvage 78-85%	Angioplasty, bypass grafts	Early revascularization recommended
<b>Riyad Karmy-Jones et al., 2024</b>	Revascularization (direct or indirect)	Wound bed vessels	Not mentioned	Not mentioned	Before and 1 week after intervention
<b>K. Chae et al., 2016</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>A. Caetano et al., 2020</b>	Endovascular revascularization	Not specified	Higher healing with successful revascularization	Not specified	Not specified
<b>M. Fujii et al., 2021</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>N. Troisi et al., 2021</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Mohammed Shahat et al., 2024</b>	Endovascular	Pedal arteries	77.3% (pedal angioplasty), 81.7% (PAR)	Pedal angioplasty	Not explicit
<b>V. Alexandrescu et al., 2019</b>	Endovascular (WTR and IR)	Pedal and ankle circulation	91% overall success	Angiosome-oriented reperfusion	Mean follow-up 10.9 months
<b>R. Hinchliffe et al., 2012</b>	Endovascular, open bypass surgery	Not mentioned	Limb salvage rates 78-85%	Not mentioned	Not mentioned
<b>Mohamed Fathy Abdelghaffar et al., 2023</b>	Endovascular	Pedal arch	Healing rates 50-91.7%	Balloon angioplasty	Not mentioned
<b>V. Chuter et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>G. Andros et al., 2004</b>	Surgical bypass	Pedal arteries	85-90% 3-year limb-salvage	Pedal bypass with autogenous conduits	Not mentioned
<b>K. Claesson et al., 2011</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>T. Elgzyri et al., 2014</b>	Endovascular (PTA), Surgical bypass	Foot/ankle circulation	Not specified	PTA, Reconstructive surgery	Median 8 weeks from inclusion
<b>T. Nakama et al., 2017</b>	Endovascular (angioplasty)	Pedal arteries	Higher healing rate (57.5% vs 37.3%)	Pedal artery angioplasty (PAA)	Not explicit
<b>H. Jung et al., 2019</b>	Endovascular	Infrapopliteal arteries	PAR achieved in 60.9%	Subintimal angioplasty, pedal-plantar loop technique	Part of treatment for chronic wounds
<b>Michael Rouse et al., 2024</b>	Endovascular	Anterior tibial, SFA, popliteal arteries	94% technical success	Balloon angioplasty +/- stenting	Follow-up at mean of 89 days
<b>V. Alexandrescu et al., 2009</b>	Endovascular	Lower limb arteries	84% initial technical success	Subintimal (SA) and endoluminal (EA) angioplasty	Initial treatment strategy

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
Danlan Pu et al., 2019	Endovascular (angioplasty)	Pedal or below-knee arteries	Not mentioned	Angioplasty	Not mentioned
Ridho Sinaga et al., 2021	Endovascular (PTA)	Pedal or below-knee arteries	Improvement in PEDIS scores	Angioplasty	Shortly after ulcer presentation
O. Galimov et al., 2021	Endovascular	Below-knee arteries	66.7% limb salvage rate	Balloon angioplasty	After ulcer presentation
S. Spiliopoulos et al., 2023	Endovascular	Anterior and posterior tibial arteries	96.4% 6-month limb salvage	Not specified	Not explicit
F. Álvaro-Afonso et al., 2024	Endovascular	Femoropopliteal, infrapopliteal, tibial arteries	71.43% healing rate	POBA, DCB, stenting	Part of treatment protocol
Tracy J. Cheun et al., 2024	Likely endovascular	Tarsal vessels	91% technical success	Not explicit	Concomitant with tibial interventions

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>B. Dong et al., 2022</b>	Endovascular (PTA)	Femoral-popliteal, inferior knee arteries	Shorter healing time with PTA-VSD	Angioplasty	Part of "one-stop" strategy
<b>Jon C. Henry et al., 2016</b>	Surgical bypass, endovascular	Pedal arteries	Improved healing with prior endovascular intervention	Not specified	Prior to surgical bypass
<b>J. Vouillarmet et al., 2016</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Thomas Collins et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>M. Sabry et al., 2023</b>	Endovascular	Pedal arteries	Higher healing rate (89%)	Not specified	Not specified

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Rongzhi Wen et al., 2023</b>	Endovascular, surgical bypass	Not specified	Poor clinical results	Stenting, angioplasty, bypass grafting	Not specified
<b>M. E. Yamany et al., 2020</b>	Endovascular revascularization	Pedal arteries	Complete PAA in 33%	Angioplasty of pedal arteries	Evaluated over follow-up period
<b>Keisuke Miyake et al., 2024</b>	Surgical bypass	Below-knee arteries	Not mentioned	Bypass surgery distal to popliteal arteries	Not mentioned
<b>B. Vijaynagar et al., 2019</b>	Vascular surgery/angiogram (implying endovascular)	Not specified	Not specified	Not specified	Not specified
<b>M. N. Bouayed et al., 2019</b>	Surgical bypass, endovascular, hybrid	Pedal and below-knee arteries	88% primary limb salvage	Conventional surgery, angioplasty	Not explicit

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Pam Chen et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>J. Brownrigg et al., 2013</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>M. Doyle et al., 2020</b>	Endovascular intervention	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Alexander T. Hong et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>N. Troisi et al., 2021a</b>	Endovascular revascularization	Femoro-popliteal and below-the-knee arteries	62.5% healing at 6 months	Isolated femoro-popliteal revascularization	Not explicit
<b>Fengjie Tang et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Rushabh A Parekh et al., 2024</b>	Endovascular (angioplasty), surgical bypass	Lower leg arteries	Not mentioned	Angioplasty, stent placement, bypass surgery	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>R. Jarosiková et al., 2025</b>	Endovascular (PTA)	Not explicit	Not mentioned	PTA	Follow-up at 3 and 6 months
<b>E. Iacopi et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Mwidimi Ndosi et al., 2017</b>	Revascularization surgery	Not specified	Not specified	Not specified	Not specified
<b>Hendri et al., 2023</b>	Revascularization	Not specified	Not specified	Not specified	Not specified
<b>Stephanie Mae Macfarlane et al., 2024</b>	Vascular intervention	Not specified	Not specified	Not specified	Not specified
<b>P. Faries et al., 2004</b>	Revascularization	Not specified	Not specified	Not specified	Not specified
<b>Mohamed Elyamany et al., 2025</b>	Revascularization	Not specified	Not specified	Not specified	Not specified
<b>H. Mohafez et al., 2018</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Sijie Yang et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Andreia Pinelo et al., 2024a</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Rachael O. Forsythe et al., 2016</b>	Endovascular (angioplasty), surgical bypass	Not mentioned	Not mentioned	Angioplasty, surgical bypass	Not mentioned
<b>Marta Carmena-Pantoja et al., 2021</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>K. Spanos et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Odette Hart et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>P. Ince et al., 2007</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Rachael O. Forsythe et al., 2020a</b>	Revascularization	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>K. Marmagkiolis et al., 2017</b>	Endovascular	Anterior tibial, dorsalis pedis, posterior tibial	92.6% success rate	Implied angioplasty +/- stenting	Not mentioned
<b>Nicole K. Cates et al., 2019</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>M. Meloni et al., 2021</b>	Endovascular and surgical bypass	Pedal and below-knee arteries	Not mentioned	Not specified	Not specified
<b>A. Hartemann-Heurtier et al., 2002</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>C. Gazzaruso et al., 2020</b>	Revascularization	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Yan Chen et al., 2019</b>	Revascularization as part of standard care	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Eduardo Silva et al., 2025</b>	Revascularization	Pedal arteries	Not mentioned	Not mentioned	Not mentioned
<b>B. Lin et al., 2020</b>	Angioplasty	Not mentioned	Not mentioned	Angioplasty	Not mentioned
<b>R. Somayaji et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>P. Normahani et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Yingzhou Liu et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Sichun Zhao et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>D. Lowry et al., 2018</b>	Endovascular (PTA)	Below-knee arteries	Improved microvascular reactivity	Angioplasty	After ulcer presentation

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Jason Zhang et al., 2024</b>	Endovascular and surgical bypass	Aortoiliac, femoropopliteal, tibial	66.7% healing in revascularized patients	Angioplasty, atherectomy, stent, bypass	Not mentioned
<b>Raffaele Grande et al., 2020</b>	Endovascular	SFA, PTA, peroneal artery	Patency of treated vessels restored	Angioplasty (PTA), stenting	Part of treatment for non-healing ulcers
<b>Yan-Bin Wang et al., 2024</b>	Conservative management	Not specified	Not mentioned	Antiplatelets, vasodilators	Not explicit
<b>M. Doyle et al., 2020a</b>	Endovascular revascularization	Aortoiliac, femoropopliteal, infrapopliteal	No significant correlation with outcomes	Not specified	Up to 90 days prior to amputation
<b>N. Akhtar et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>García-Sáenz Mc et al., 2004</b>	Surgical bypass, Endovascular (angioplasty)	Not mentioned	Not mentioned	Distal bypass, Angioplasty	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
J. Brownrigg et al., 2015	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
A. Brechow et al., 2013	Endovascular, surgical bypass, conservative	Infrapopliteal, iliacal, femoral arteries	Not mentioned	PTA, bypass reconstructions	Not explicit
Jason Chow et al., 2024	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
Junpeng Liu et al., 2024	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
D. Margolis et al., 2002	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
F. Game et al., 2016	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
R. Snyder et al., 2009	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
L. Prompers et al., 2008	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
Pamela Chen et al., 2023	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
S. H. Lu et al., 2017	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
D. Margolis et al., 2005	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
P. Lazzarini et al., 2020	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
T. Kwan et al., 2015	Endovascular	Pedal arteries	84% success rate	Atherectomy, angioplasty, stenting	Not mentioned
V. Chuter et al., 2023a	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
W. Bevan et al., 2008	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
R. Snyder et al., 2010	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
Jasper A Sung et al., 2020	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>N. Santamaria et al., 2004</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>R. Warriner et al., 2011</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Seoyoung C. Kim et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>S. Zimny et al., 2005</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>L. Ribu et al., 2008</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>T. Elgyri et al., 2013</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Betiel K. Fesseha et al., 2018</b>	Endovascular, open bypass, endarterectomy	Not specified	Not specified	Debridement, minor amputation, skin grafting	Not specified
<b>J. Lindberg et al., 2021</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

<b>Citation</b>	<b>Intervention Type</b>	<b>Target Vessels</b>	<b>Technical Success Rate</b>	<b>Procedural Details</b>	<b>Timing Relative to Ulcer Onset</b>
<b>Martin C. Robson et al., 2000</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Hsi-An Yang et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>D. Wukich et al., 2014</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>V. E. Parks et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>J. Reekers et al., 2013</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>V. Venkatesan et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>B. Aliahmad et al., 2018</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>J. Reekers et al., 2016</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

<b>Citation</b>	<b>Intervention Type</b>	<b>Target Vessels</b>	<b>Technical Success Rate</b>	<b>Procedural Details</b>	<b>Timing Relative to Ulcer Onset</b>
<b>A. MacDonald et al., 2019</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>N. Kontopodis et al., 2016</b>	Autologous platelet-rich plasma (PRP)	Not mentioned	Not mentioned	Local growth factors	Not mentioned
<b>Scott J Edwards et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>H. Elghazaly et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Aditya Dutta et al., 2021</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Nantawan Koonalinthip et al., 2021</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>O. Oncul et al., 2007</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

<b>Citation</b>	<b>Intervention Type</b>	<b>Target Vessels</b>	<b>Technical Success Rate</b>	<b>Procedural Details</b>	<b>Timing Relative to Ulcer Onset</b>
<b>Ivana Roth-Albin et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Nila N. Sari et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>S. Mehta et al., 2010</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Patricia M González-Villacorta et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>C. Hicks et al., 2018</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>S. Engberg et al., 2019</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>D. Armstrong et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Dr. Madhuri Jain et al., 2022</b>	Conservative, invasive procedures	Lower limb vessels	Not mentioned	Stenting, embolectomy, bypass	Not mentioned
<b>Lucia Bubulac et al., 2025</b>	Surgical decompression	Not specified	Not specified	Not specified	Not specified
<b>Olivia V. Waldman et al., 2020</b>	Operative intervention	Not specified	Not specified	Not specified	Not specified
<b>Jacqueline N. McNulty et al., 2018</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Yumika Nishio et al., 2022</b>	Endovascular therapy (EVT), surgical bypass	Not mentioned	Healing rates: EVT 26.7%, bypass 65.0%	Not mentioned	Not mentioned
<b>Rona Kartika et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

<b>Citation</b>	<b>Intervention Type</b>	<b>Target Vessels</b>	<b>Technical Success Rate</b>	<b>Procedural Details</b>	<b>Timing Relative to Ulcer Onset</b>
<b>Arthur C Yelland et al., 2022</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>F. Game et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Sebastián Flores-Escobar et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>David A. Reiter et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>J. A. Cheong et al., 2022</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Bhavani Prasad Mahindrakar et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Aroa Tardáguila-García et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Jarrod M. Shapiro et al., 2011</b>	Revascularization	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Sooraj M Shah et al., 2019</b>	Transpedal and femoral access for interventions	Infrainguinal arteries	Not specified	Endovascular treatment	Not specified
<b>Jiyong Ahn et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Aroa Tardáguila-García et al., 2022</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Jiyong Ahn et al., 2024</b>	Negative pressure wound therapy (NPWT)	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>A. Liakos et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>A. M. Mahon et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>T. Macioch et al., 2015</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Sofija Pejkova et al., 2025</b>	Surgical decompression	Posterior tibial artery	High healing rates (55% complete, 45% with 83% reduction)	Dellon Decompression of medial ankle tunnels	Ulcers averaged 17.1 months in duration
<b>Mariyam Iqbal et al., 2024</b>	Conservative surgery, early surgical intervention	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
Hanan Ansari et al., 2025	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
N. Leone et al., 2025	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
Jessica M. Eager et al., 2025	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
Ivan Jozic et al., 2024	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
Максим Борисович Горобейко et al., 2014	Ultrasound debridement, P romogran dressing, Drug revascularization	Not mentioned	Not mentioned	Not mentioned	Not mentioned
Tawfik Abo Mera et al., 2019	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

<b>Citation</b>	<b>Intervention Type</b>	<b>Target Vessels</b>	<b>Technical Success Rate</b>	<b>Procedural Details</b>	<b>Timing Relative to Ulcer Onset</b>
<b>Nasibeh Vatankhah et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>S. Brown et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Asmat Burhan et al., 2023</b>	Compression therapy, compression stockings	Not mentioned	Not mentioned	Not specified	Not mentioned
<b>M. DeSanto et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Stephanie P. Hao et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>P. Tappia et al., 2021</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Vishnu S. Ravidas et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

Citation	Intervention Type	Target Vessels	Technical Success Rate	Procedural Details	Timing Relative to Ulcer Onset
<b>Takeshi Fukuda et al., 2019</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Tze-Woei Tan et al., 2022</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Yan Mi et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Kaitlyn K Rogers et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
<b>Ivan Y. Luu et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned

### Radiological Assessment Methods

A variety of radiological and related non-invasive modalities were used across the studies to assess vascular status and wound healing. Duplex ultrasound (DUS) was a commonly employed tool, used to assess vessel patency, ankle-brachial index (ABI), and, more recently, pedal acceleration time (PAT). PAT, in particular, was highlighted as a promising non-invasive predictor of wound healing, especially in patients with non-compressible arteries. Angiography, including digital subtraction angiography (DSA) and CT angiography (CTA), was used for detailed anatomical delineation of occlusive disease and to assess the status of the pedal arch. Some studies

also utilized MRI and magnetic resonance angiography (MRA) for assessing perfusion and microvascular function.

Specific measurements included time-density curves from 2D perfusion angiography, MAC scores from plain radiographs, and vessel runoff scores from angiograms. Other functional assessments included transcutaneous oximetry (TcPO<sub>2</sub>) and skin perfusion pressure (SPP). Assessment timing typically included baseline measurements prior to intervention, immediate post-procedural evaluations, and scheduled follow-ups at intervals ranging from one to 24 months. There was little to no reporting on who performed the assessments or data on inter-observer reliability, indicating a potential for measurement inconsistency across the literature.

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
<b>N. Troisi et al., 2018</b>	Angiography, Duplex ultrasound	Time to healing, Mean time to healing	Discharge, 1, 6, 12 months, then yearly
<b>J. Apelqvist et al., 2011</b>	Not mentioned	Not mentioned	Not mentioned
<b>Rachael O. Forsythe et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned
<b>Jennifer Skolnik et al., 2021</b>	Plain radiographs	MAC score	Not mentioned
<b>N. Troisi et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned
<b>S. Jacqueminet et al., 2005</b>	Arteriography	Patent pedal vessel	Before PTA and during follow-up
<b>E. Saricilar et al., 2023</b>	Not mentioned	TcPO <sub>2</sub> , ABI	Not mentioned

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
Jill Sommerset et al., 2020	Duplex ultrasound	Pedal acceleration time (PAT)	Before and after interventions
Andreia Pinelo et al., 2024	Not mentioned	Not mentioned	Not mentioned
Shiping Ji et al., 2022	Angiography	Not mentioned	Not mentioned
Osama A. Ismail et al., 2020	Duplex ultrasound, CT angiography	ABI, lesion characteristics	Pre-intervention, 3, 6, 9, 12 months
M. Ghweeba et al., 2022	Duplex ultrasound	Not mentioned	Discharge, 1, 3, 6, 12 months
Chang Sik Shin et al., 2025	Not mentioned	Not mentioned	Not mentioned
Ahmed Hossny et al., 2019	CT angiography, Duplex ultrasound	Vessel patency, ABI	Baseline, 2, 4, 6 months
B. Y. C. Khor et al., 2017	Not mentioned	Not mentioned	Not mentioned
M. Söderström et al., 2013	Angiograms	Not mentioned	Not mentioned

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
Limi Lee et al., 2024	Digital subtraction angiography	Complete pedal arch prevalence	6, 12, 24 months
K. Dell et al., 2021	Duplex ultrasound	Pedal acceleration time (PAT)	Baseline, 4-6 weeks follow-up
R. Hinchliffe et al., 2016	Not mentioned	Not mentioned	Not mentioned
Riyad Karmy-Jones et al., 2024	Duplex ultrasound	Pedal acceleration time (PAT)	Before and 1 week after intervention
K. Chae et al., 2016	Not mentioned	Not mentioned	Not mentioned
A. Caetano et al., 2020	Not mentioned	Not mentioned	Not mentioned
M. Fujii et al., 2021	Not mentioned	Skin perfusion pressure, CRP levels	Pre- and post-operative
N. Troisi et al., 2021	Angiograms	Not mentioned	Not mentioned
Mohammed Shahat et al., 2024	Angiography	Vessel patency	Not specified
V. Alexandrescu et al., 2019	Not mentioned	Not mentioned	Not mentioned
R. Hinchliffe et al., 2012	Not mentioned	Not mentioned	Not mentioned

<b>Citation</b>	<b>Imaging Modality</b>	<b>Specific Measurements</b>	<b>Assessment Timing/Frequency</b>
<b>Mohamed Fathy Abdelghaffar et al., 2023</b>	Duplex ultrasound, CT angiography	Not mentioned	Not mentioned
<b>V. Chuter et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned
<b>G. Andros et al., 2004</b>	Duplex US, MRA, contrast arteriography	Not mentioned	Not mentioned
<b>K. Claesson et al., 2011</b>	Not mentioned	Not mentioned	Not mentioned
<b>T. Elgzyri et al., 2014</b>	Not mentioned	Not mentioned	Not mentioned
<b>T. Nakama et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned
<b>H. Jung et al., 2019</b>	Not mentioned	Not mentioned	Not mentioned
<b>Michael Rouse et al., 2024</b>	Direct pressure measurement via sheath transducer	Hemodynamic pressure changes	Initial and post-intervention
<b>V. Alexandrescu et al., 2009</b>	Duplex ultrasound	Vessel patency	Every 6 months
<b>Danlan Pu et al., 2019</b>	Not mentioned	ABI, TcPO2	Not mentioned
<b>Ridho Sinaga et al., 2021</b>	Not mentioned	PEDIS score	Pre- and post-angioplasty

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
<b>O. Galimov et al., 2021</b>	Invasive pressure monitoring during X-ray endovascular interventions	Stenosis significance	Intraoperative
<b>S. Spiliopoulos et al., 2023</b>	Doppler ultrasound (DUS)	Pulsatility index (PI), Pedal acceleration time (PAT)	Pre-, post-procedural, 6-month follow-up
<b>F. Álvaro-Afonso et al., 2024</b>	Not mentioned	TP, AP, ABPI, TBPI, TcPO <sub>2</sub> , SPP	Before and 4 weeks after revascularization
<b>Tracy J. Cheun et al., 2024</b>	Angiograms	Pedal runoff scores	Pre- and post-intervention
<b>B. Dong et al., 2022</b>	Not mentioned	ABI, ulcer score	Pre- and post-surgery; 3, 6, 12 months
<b>Jon C. Henry et al., 2016</b>	Not mentioned	Runoff scores	Not mentioned
<b>J. Vouillarmet et al., 2016</b>	Not mentioned	Not mentioned	Not mentioned
<b>Thomas Collins et al., 2024</b>	Not mentioned	pMAC score	Not mentioned
<b>M. Sabry et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned

<b>Citation</b>	<b>Imaging Modality</b>	<b>Specific Measurements</b>	<b>Assessment Timing/Frequency</b>
<b>Rongzhi Wen et al., 2023</b>	Not mentioned	Trabecular area, ABI	Pre- and post-treatment
<b>M. E. Yamany et al., 2020</b>	CTA, Duplex ultrasound	Vessel patency (pedal arch status), ABI	Baseline, post-intervention, monthly up to 6 months
<b>Keisuke Miyake et al., 2024</b>	Angiography	Pedal circulation status (visualized vs non-visualized perfusion)	6 months postoperatively
<b>B. Vijaynagar et al., 2019</b>	Angiogram	Not mentioned	Not mentioned
<b>M. N. Bouayed et al., 2019</b>	Not mentioned	Not mentioned	Not mentioned
<b>Pam Chen et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned
<b>J. Brownrigg et al., 2013</b>	Not mentioned	Not mentioned	Not mentioned
<b>M. Doyle et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned
<b>Alexander T. Hong et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
<b>N. Troisi et al., 2021a</b>	2D perfusion angiography	Time–density curves	Baseline and post-intervention, 6-month follow-up
<b>Fengjie Tang et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned
<b>Rushabh A Parekh et al., 2024</b>	Doppler scans, CT angiography	ABPI, TBI values	Baseline and after 3 months
<b>R. Jarosiková et al., 2025</b>	Plain radiographs	MAC scoring system	3 and 6 months post-PTA
<b>E. Iacopi et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned
<b>Mwidimi Ndosoi et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned
<b>Hendri et al., 2023</b>	Not mentioned	Wifl score	Not mentioned
<b>Stephanie Mae Macfarlane et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned
<b>P. Faries et al., 2004</b>	Not mentioned	Not mentioned	Not mentioned
<b>Mohamed Elyamany et al., 2025</b>	Duplex ultrasound	Pedal acceleration time (PAT)	Not mentioned
<b>H. Mohafez et al., 2018</b>	High-frequency ultrasound	Wound area and depth	Not mentioned

<b>Citation</b>	<b>Imaging Modality</b>	<b>Specific Measurements</b>	<b>Assessment Timing/Frequency</b>
<b>Sijie Yang et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned
<b>Andreia Pinelo et al., 2024a</b>	Ultrasound	Pedal Acceleration Time (PAT)	12-16 weeks after first evaluation
<b>Rachael O. Forsythe et al., 2016</b>	MRA, CTA, DSA	Vessel patency	Not mentioned
<b>Marta Carmena-Pantoja et al., 2021</b>	Not mentioned	Radiographic arterial calcification (RAC)	Not mentioned
<b>K. Spanos et al., 2017</b>	Not mentioned	ABI, popliteal pulse palpation	Not mentioned
<b>Odette Hart et al., 2024</b>	Not mentioned	Pedal Acceleration Time (PAT)	Not mentioned
<b>P. Ince et al., 2007</b>	Not mentioned	Not mentioned	Not mentioned
<b>Rachael O. Forsythe et al., 2020a</b>	Not mentioned	SPP, toe pressure, TcPO <sub>2</sub> , ankle pressure, ABI	Not mentioned
<b>K. Marmagkiolis et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned
<b>Nicole K. Cates et al., 2019</b>	Angiography	Not mentioned	Not mentioned

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
<b>M. Meloni et al., 2021</b>	duplex US, CT, MRI	Not mentioned	Not mentioned
<b>A. Hartemann-Heurtier et al., 2002</b>	Not mentioned	Not mentioned	Not mentioned
<b>C. Gazzaruso et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned
<b>Yan Chen et al., 2019</b>	CT angiography and perfusion imaging	Vessel density, blood flow, blood volume	12 weeks postoperatively
<b>Eduardo Silva et al., 2025</b>	Not mentioned	Pedal acceleration time (PAT)	Not mentioned
<b>B. Lin et al., 2020</b>	Wearable near-infrared spectroscopy (NIRS)	Hemoglobin levels, tissue blood volume, tissue oxygen concentration	Not mentioned
<b>R. Somayaji et al., 2017</b>	Not mentioned	Doppler waveforms	Not mentioned
<b>P. Normahani et al., 2020</b>	Duplex ultrasound (DUS)	Vessel calcification, patent vessels, waveform features	Baseline scans, 12-month review

<b>Citation</b>	<b>Imaging Modality</b>	<b>Specific Measurements</b>	<b>Assessment Timing/Frequency</b>
<b>Yingzhou Liu et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned
<b>Sichun Zhao et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned
<b>D. Lowry et al., 2018</b>	Laser Doppler fluxmetry	Time to maximum flux (TtM)	Monthly until healing
<b>Jason Zhang et al., 2024</b>	Not mentioned	ABI, pedal pulse palpation	Not mentioned
<b>Raffaele Grande et al., 2020</b>	B-mode US, colour imaging, arteriography	Vessel patency	Not explicit
<b>Yan-Bin Wang et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned
<b>M. Doyle et al., 2020a</b>	Not mentioned	TASC classifications	Not mentioned
<b>N. Akhtar et al., 2020</b>	Not mentioned	Ulcer dimensions	Before procedure, then every 5 days
<b>García-Sáenz Mc et al., 2004</b>	Not mentioned	Not mentioned	Not mentioned
<b>J. Brownrigg et al., 2015</b>	Not mentioned	Not mentioned	Not mentioned

<b>Citation</b>	<b>Imaging Modality</b>	<b>Specific Measurements</b>	<b>Assessment Timing/Frequency</b>
<b>A. Brechow et al., 2013</b>	Not mentioned	ABI, Doppler flow curve	At baseline
<b>Jason Chow et al., 2024</b>	X-ray, CT	Not mentioned	Not mentioned
<b>Junpeng Liu et al., 2024</b>	Angiography, B-ultrasound, X-rays	Not mentioned	Baseline and post-intervention
<b>D. Margolis et al., 2002</b>	Not mentioned	Wound size, grade	Not mentioned
<b>F. Game et al., 2016</b>	Not mentioned	Not mentioned	Not mentioned
<b>R. Snyder et al., 2009</b>	Not mentioned	Not mentioned	Not mentioned
<b>L. Prompers et al., 2008</b>	Not mentioned	Not mentioned	Not mentioned
<b>Pamela Chen et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned
<b>S. H. Lu et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned
<b>D. Margolis et al., 2005</b>	Not mentioned	Not mentioned	Not mentioned
<b>P. Lazzarini et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned

<b>Citation</b>	<b>Imaging Modality</b>	<b>Specific Measurements</b>	<b>Assessment Timing/Frequency</b>
<b>T. Kwan et al., 2015</b>	Ultrasound	Access artery patency	Before procedure and at 1-month follow-up
<b>V. Chuter et al., 2023a</b>	Not mentioned	Not mentioned	Not mentioned
<b>W. Bevan et al., 2008</b>	Weightbearing radiographs	Lateral talar-first metatarsal angle	Not mentioned
<b>R. Snyder et al., 2010</b>	Not mentioned	Percent area reduction (PAR)	Weeks 1-4 and 12
<b>Jasper A Sung et al., 2020</b>	Not mentioned	Wound size reduction	Not mentioned
<b>N. Santamaria et al., 2004</b>	Digital wound imaging system	Not mentioned	Every 2 weeks
<b>R. Warriner et al., 2011</b>	Not mentioned	Percent area reduction (PAR)	Weeks 4, 6, 8, 12
<b>Seoyoung C. Kim et al., 2017</b>	Periflux System 5000 (not imaging)	Transcutaneous oxygen tension (TcPO <sub>2</sub> )	Baseline, days 1, 3, 7, 14, 28
<b>S. Zimny et al., 2005</b>	Not mentioned	Planimetric wound area	Not mentioned
<b>L. Ribu et al., 2008</b>	Not mentioned	Not mentioned	Not mentioned
<b>T. Elgzyri et al., 2013</b>	Not mentioned	Toe/ankle pressure	At presentation

<b>Citation</b>	<b>Imaging Modality</b>	<b>Specific Measurements</b>	<b>Assessment Timing/Frequency</b>
<b>Betiel K. Fesseha et al., 2018</b>	Not mentioned	Not mentioned	Not mentioned
<b>J. Lindberg et al., 2021</b>	Fluorescence imaging	Ingress rate (IR), time to first blush	Not mentioned
<b>Martin C. Robson et al., 2000</b>	Not mentioned	Wound closure percentage	20-week period
<b>Hsi-An Yang et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned
<b>D. Wukich et al., 2014</b>	Weight-bearing radiographs	Various angles (e.g., lat-talar 1st met angle, cuboid height)	Not mentioned
<b>V. E. Parks et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned
<b>J. Reekers et al., 2013</b>	Not mentioned	Not mentioned	Not mentioned
<b>V. Venkatesan et al., 2023</b>	Not mentioned	Not mentioned	Not mentioned
<b>B. Aliahmad et al., 2018</b>	Thermal and color imaging	Wound area, temperature distribution	Baseline, week 2, week 4
<b>J. Reekers et al., 2016</b>	Color Doppler US, CTA, MRA	Not mentioned	Not mentioned

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
<b>A. MacDonald et al., 2019</b>	Not mentioned	Not mentioned	Not mentioned
<b>N. Kontopodis et al., 2016</b>	Not mentioned	Not mentioned	Not mentioned
<b>Scott J Edwards et al., 2023</b>	MRI (IVIM, BOLD)	Perfusion indices	Not mentioned
<b>H. Elghazaly et al., 2023</b>	Podiatry ankle duplex scan (PAD-scan)	Waveforms (monophasic, biphasic, triphasic)	12-month follow-up
<b>Aditya Dutta et al., 2021</b>	Wound zoom camera	Ulcer area	Baseline, 4 weeks, 12 weeks
<b>Nantawan Koonalinthip et al., 2021</b>	Not mentioned	Wound radius reduction, 50% area reduction	Every 4 weeks
<b>O. Oncul et al., 2007</b>	Not mentioned	Not mentioned	Not mentioned
<b>Ivana Roth-Albin et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned
<b>Nila N. Sari et al., 2025</b>	Photographic, hyperspectral, and thermal imaging	Wound area, biochemical insight	Not specified

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
S. Mehta et al., 2010	Not mentioned	Not mentioned	Not mentioned
Patricia M González-Villacorta et al., 2025	Hyperspectral Imaging (HSI)	Not mentioned	Not mentioned
C. Hicks et al., 2018	Not mentioned	Not mentioned	Not mentioned
S. Engberg et al., 2019	Not mentioned	Not mentioned	Not mentioned
D. Armstrong et al., 2020	Photography	Wound area	Weekly
Dr. Madhuri Jain et al., 2022	Doppler, digital subtraction angiography	Blood flow velocity/direction, BP at ankle/wrist	Not specified
Lucia Bubulac et al., 2025	Doppler ultrasound	Arterial and venous blood flow	Baseline, 4 weeks, 8 weeks
Olivia V. Waldman et al., 2020	Not mentioned	Not mentioned	Not mentioned
Jacqueline N. McNulty et al., 2018	Not mentioned	Not mentioned	Not mentioned
Yumika Nishio et al., 2022	Not mentioned	Not mentioned	Not mentioned

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
<b>Rona Kartika et al., 2020</b>	Digital images (ImageJ)	Wound area, granulation area, granulation index	Baseline, day 3, 7, 14
<b>Arthur C Yelland et al., 2022</b>	Not mentioned	Not mentioned	Not mentioned
<b>F. Game et al., 2020</b>	Not mentioned	Not mentioned	Not mentioned
<b>Sebastián Flores-Escobar et al., 2025</b>	Not mentioned	Wound area, granulation tissue, TcPO2	12-week period
<b>David A. Reiter et al., 2025</b>	MRI	Resting perfusion, microvascular function	Baseline
<b>J. A. Cheong et al., 2022</b>	Not mentioned	ABI	Baseline
<b>Bhavani Prasad Mahindrakar et al., 2023</b>	Not mentioned	Wound pH, surface temperature	Weekly for 4 weeks
<b>Aroa Tardáguila-García et al., 2023</b>	Simple X-ray	Periosteal reaction, sequestrum, cortical disruption, etc.	Twice-weekly until healing

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
Jarrold M. Shapiro et al., 2011	US, MRA, CTA, laser speckle perfusion imaging	Not mentioned	Not mentioned
Sooraj M Shah et al., 2019	Not mentioned	Not mentioned	Not mentioned
Jiyong Ahn et al., 2025	Infrared 3D camera	Wound area and volume	Weekly for 1 month
Aroa Tardáguila-García et al., 2022	Plain X-rays	Periosteal reaction, sequestrum, cortical disruption	1-year follow-up
Jiyong Ahn et al., 2024	Infra-red 3D camera	Wound area and volume	Weekly for one month
A. Liakos et al., 2020	Not mentioned	Not mentioned	Not mentioned
A. M. Mahon et al., 2017	Not mentioned	Ankle-Brachial Pressure Index	Not mentioned
T. Macioch et al., 2015	Not mentioned	Wound diameter measurements	Not mentioned
Sofija Pejkova et al., 2025	Doppler ultrasonography	Blood flow in posterior tibial artery	Pre-op, 6 months, 9 months

<b>Citation</b>	<b>Imaging Modality</b>	<b>Specific Measurements</b>	<b>Assessment Timing/Frequency</b>
<b>Mariyam Iqbal et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned
<b>Hanan Ansari et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned
<b>N. Leone et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned
<b>Jessica M. Eager et al., 2025</b>	Not mentioned	Not mentioned	Not mentioned
<b>Ivan Jozic et al., 2024</b>	EKARE inSight imaging	Wound size change	Weekly for 4 weeks
<b>Максим Борисович Горобейко et al., 2014</b>	Not mentioned	Transcutaneous oxygen pressure (PtcO <sub>2</sub> )	Not mentioned
<b>Tawfik Abo Mera et al., 2019</b>	Not specified	Ankle peak systolic velocity	Not specified
<b>Nasibeh Vatankhah et al., 2017</b>	Not mentioned	Not mentioned	Not mentioned
<b>S. Brown et al., 2025</b>	2D photography	Healing status, confidence rating	Not mentioned

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
Asmat Burhan et al., 2023	Not mentioned	Ankle Brachial Index, Bates-Jensen Wound Assessment Tool	Pre- and post-test over 8 weeks
M. DeSanto et al., 2020	Not mentioned	Not mentioned	Not mentioned
Stephanie P. Hao et al., 2020	Not mentioned	Not mentioned	Not mentioned
P. Tappia et al., 2021	Camera, NIRS, Doppler	Wound area/volume/depth, O2 sat, ABI	Baseline and monthly
Vishnu S. Ravidas et al., 2020	Not mentioned	ABPI	Not mentioned
Takeshi Fukuda et al., 2019	MRI	Not mentioned	Not mentioned
Tze-Woei Tan et al., 2022	Not mentioned	Not mentioned	Not mentioned
Yan Mi et al., 2025	Not mentioned	Wound area, granulation tissue coverage	Not mentioned
Kaitlyn K Rogers et al., 2023	Continuous glucose monitor (CGM)	Glycemic metrics (TIR, TAR, TBR)	Not specified

Citation	Imaging Modality	Specific Measurements	Assessment Timing/Frequency
Ivan Y. Luu et al., 2024	Not mentioned	Not mentioned	Not mentioned

### Wound Healing Outcomes

Wound healing outcomes varied significantly across studies, influenced by factors such as baseline perfusion, intervention type, and patient comorbidities. Primary healing measures consistently showed better outcomes for patients with improved pedal circulation. For instance, studies assessing pedal arch patency reported significantly higher healing rates and shorter time to healing in patients with a complete pedal arch (CPA) compared to those with incomplete (IPA) or absent (APA) arches. Healing rates within 3 months were 50% for CPA versus 20% for APA ( $p=0.01$ ), and overall healing rates reached 93.3% for CPA versus 52.6% for APA ( $p=0.003$ ). Similarly, mean time to healing was shorter in CPA groups (3.5 months) compared to APA groups (5.7 months) ( $p<0.001$ ). Successful pedal artery revascularization (PAR) also resulted in a higher wound healing rate (86.7% vs 59.1%;  $P=0.007$ ) compared to unsuccessful PAR. Angiosome-targeted revascularization approaches were associated with better wound healing outcomes (HR 1.97; 95% CI, 1.34-2.90) and shorter healing times compared to indirect revascularization.

Secondary outcomes, including limb salvage and amputation rates, also demonstrated a strong correlation with successful revascularization. One-year limb salvage rates were significantly better in patients with a complete pedal arch, reaching 100% in some cohorts compared to approximately 70% in those with an absent arch ( $p<0.001$ ). Major amputation rates were substantially lower following successful interventions. For example, successful PAR was associated with a major amputation rate of 5.1% versus 40.9% for unsuccessful PAR ( $p\leq 0.001$ ). Similarly, a successful endovascular revascularization group had a major amputation rate of 3.9% compared to 24.1% in a failed revascularization group ( $p<0.0001$ ). Follow-up durations ranged from several

months to multiple years, allowing for the assessment of both short-term healing and long-term limb preservation.

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>N. Troisi et al., 2018</b>	Time to complete healing, healing rates	CPA: 3.5 months, 83.3%	1-year limb salvage: CPA 100%, APA 70.1%	Mean 7.4 months	p<0.001 for healing time; p<0.001 for limb salvage
<b>J. Apelqvist et al., 2011</b>	Healing without amputation	36% healed primarily, median time 27 weeks	13% major amputation, 27% died unhealed	Until healing or death	OR for healing: PTA 1.77, surgery 2.05
<b>Rachael O. Forsythe et al., 2020</b>	Wound healing at 1 year	Median 60% (IQR 50-69%)	1-year limb salvage: 80% (endo) vs 85% (open)	Up to 5 years	Not specified
<b>Jennifer Skolnik et al., 2021</b>	Major adverse limb event (MALE)	Not mentioned	MALE in 50% at 1 year	1 year	HR for MAC score: 1.09 (95% CI 1.01-1.18)

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>N. Troisi et al., 2017</b>	Healing within 3 months	CPA 45.8% vs APA 20.7%	1-year limb salvage: CPA 100% vs APA 76.1%	1 year	p=0.009 for healing; p=0.02 for limb salvage
<b>S. Jacqueminet et al., 2005</b>	Healing rate	70% at 1 year	90% limb salvage rate at 1 year	At least 1 year	p=0.03 for patent pedal vessel
<b>E. Saricilar et al., 2023</b>	Primary wound healing, time to healing	Significant improvements	Improved limb salvage (68.8-93% at 12 mo)	Up to 12 months	p=0.011 for wound healing; p=0.001 for time to heal
<b>Jill Sommerset et al., 2020</b>	Wound healing	81.5% healing rate	18.5% amputation rate	Not mentioned	p<0.001 for PAT association with outcomes
<b>Andreia Pinelo et al., 2024</b>	Wound healing at 12 months	Shorter healing times with targeted revascularization	Not mentioned	12 months	No significant difference in 12-month healing rates

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>Shiping Ji et al., 2022</b>	Ulcer healing rate and time	P0+P1 group had higher rate and shorter time than P2	Limb salvage, survival rates compared	2 years	p=0.001 for healing rate; p=0.004 for healing time
<b>Osama A. Ismail et al., 2020</b>	Wound healing rate and time	CPA: 93.3%, 3.4 months; APA: 52.6%, 6.1 months	Limb salvage: CPA 100%, APA 68.4%	12 months	p=0.003 for healing rate; p=0.02 for healing time
<b>M. Ghweeba et al., 2022</b>	Healing rate and time	CPA: 90%, 3.7 months; APA: 54%, 6.2 months	Limb preservation: CPA 100%, APA 61.5%	12 months	p=0.004 for healing rate; p=0.03 for healing time
<b>Chang Sik Shin et al., 2025</b>	Wound healing rate	64.5% at 12 months	47 amputations (25 major)	Up to 5 years	UT grade associated with non-healing and amputation

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>Ahmed Hossny et al., 2019</b>	Complete healing at 6 months	Direct revasc: 85.71% vs Indirect: 42.85%	Limb salvage rate: 83.33% total	6 months	Not significant for healing/salvage rates
<b>B. Y. C. Khor et al., 2017</b>	Wound healing	Better with Direct Revascularization (DR)	Not mentioned	12 months	HR 1.97 (95% CI 1.34-2.90) for DR
<b>M. Söderström et al., 2013</b>	Ulcer healing rate	Direct group 72% vs Indirect 45% at 12 months	Not mentioned	12 months	HR 1.97 (95% CI 1.34-2.90), P=0.001
<b>Limi Lee et al., 2024</b>	Wound healing rate	64% at 12 months, 72% at 24 months	Not mentioned	24 months	HR for failure (complete pedal arch): 0.40 (P=0.039)

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>K. Dell et al., 2021</b>	Ulcer healing	10/11 healed with PAT <180ms; 7/8 healed post-intervention	Not mentioned	4-6 weeks	Not specified
<b>R. Hinchliffe et al., 2016</b>	Wound healing rate at 1 year	Median 60% (IQR 50-69%)	Median major amputation rate 9% at 1 year	Up to 5 years	Not specified
<b>Riyad Karmy-Jones et al., 2024</b>	Limb salvage	Not mentioned	18.5% below-knee amputation at 1 year	1 year	Limb salvage predicted by post-procedural PAT
<b>K. Chae et al., 2016</b>	Wound healing rate	Higher in angiosome-targeted group	Higher limb salvage in angiosome-targeted group	1-2 years	OR for wound healing: 3.290 (p<0.001)

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>A. Caetano et al., 2020</b>	Complete wound healing rate	53.7% (successful) vs 20.7% (failed)	Major amputation rate: 3.9% vs 24.1%	Mean ~2 years	p<0.0001 for healing and amputation rates
<b>M. Fujii et al., 2021</b>	Wound healing	Not mentioned	Not mentioned	Not mentioned	Skin perfusion pressure of 55 mmHg strongly associated with success
<b>N. Troisi et al., 2021</b>	5-year limb salvage	Not mentioned	CPA/IPA 95.1%/94.3% vs APA 67.3%	5 years	p<0.001 for limb salvage
<b>Mohammed Shahat et al., 2024</b>	Wound healing rate and time	86.7% vs 59.1% (p=0.007); time not significant	Major amputation rate: 5.1% vs 40.9% (p≤0.001)	Not mentioned	OR for failure of healing (unsuccessful PAR) = 21.64

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
V. Alexandrescu et al., 2019	Wound healing rate and time	WTR 70%, 6.8 mo vs IR 20%, 9.8 mo	Recurrence rates ~17% in all groups	Mean 10.9 months	p=0.011 for healing rates; p=0.001 for time to healing
R. Hinchliffe et al., 2012	Ulcer healing	≥60% healed at 1 year	Limb salvage rates improved compared to conservative tx	1 year	Not specified
Mohamed Fathy Abdelghaffar et al., 2023	Wound healing rate	CPA 91.7%, IPA 88.9%, APA 50%	Not mentioned	Not mentioned	Significant difference between CPA/IPA and APA
V. Chuter et al., 2023	Healing rates	Higher with DR (81-90.9%) vs IR (41-68.5%)	Mixed results for amputation	At least 6 months	One study: p=0.245 (no significant diff)

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>G. Andros et al., 2004</b>	Limb salvage	Not mentioned	85-90% three-year limb-salvage rate	3 years	Not specified
<b>K. Claesson et al., 2011</b>	Incomplete wound healing	44% did not heal	15% major amputation	Median 17 months	HR for non-healing (Wagner $\geq 3$ ): 5.8 (95% CI 2.6-12.9)
<b>T. Elgzyri et al., 2014</b>	Primary healing	45% healed primarily	16% healed after major amputation, 19% died unhealed	Until healing or death	Time to intervention <8 weeks related to healing (p<0.001)
<b>T. Nakama et al., 2017</b>	Wound healing rate and time	PAA: 57.5%, 211 days vs No-PAA: 37.3%, 365 days	Not mentioned	Not mentioned	p=0.003 for rate; p=0.008 for time

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>H. Jung et al., 2019</b>	Wound healing rate	Successful PAR 76.0% vs No-PAR 67.0%	Freedom from major amputation: PAR 96.3% vs No-PAR 84.2%	1 year	HR for healing (successful PAR): 1.564 (p=0.022)
<b>Michael Rouse et al., 2024</b>	Not mentioned	Not mentioned	No major amputations; 21.4% repeat intervention	Mean 89 days	p<0.001 for pre- vs post-intervention pressure
<b>V. Alexandrescu et al., 2009</b>	Clinical success rate	86% at 12 months, 69% at 48 months	Limb salvage: 89% at 12 mo, 80% at 48 mo	Mean 22.1 months	Patency negatively affected by lesion length >10cm (p<0.0001)
<b>Danlan Pu et al., 2019</b>	Heal rate	Group B (APG) improved vs A & C (p<0.05)	Major amputation improved in Group C (p<0.05)	6 months	Not specified

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
Ridho Sinaga et al., 2021	PEDIS score improvement	Not mentioned	Not mentioned	2 weeks	Mean PEDIS score improvement: 2.01 points (p<0.001)
O. Galimov et al., 2021	Limb salvage rate	Not mentioned	Intervention 66.7% vs Control 41.7%	Up to 24 months	p < 0.05
S. Spiliopoulos et al., 2023	Complete wound healing	38.1% at 6 months	Limb salvage 96.4% at 6 months, 92.4% at 12 months	12 months	PAT/PI had strong correlation but not significant (p>0.3)
F. Álvaro-Afonso et al., 2024	Healing rate	71.43%; median time 12 weeks	Amputation rate 14.3%	6 months	Not specified
Tracy J. Cheun et al., 2024	Ulcer healing at 3 months	55% (poor runoff w/ intervention) vs 25% (no intervention)	5-year AFS: 38% vs 11%	5 years	p=0.001 for 3-month healing; p=0.003 for 5-year AFS

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>B. Dong et al., 2022</b>	Ulcer healing time and rate	PTA-VSD: 154.79 days, 52% at 180 days	1 amputation in PTA-UD group, 0 in PTA-VSD group	12 months	p=0.002 for healing rate
<b>Jon C. Henry et al., 2016</b>	Wound healing	67.8% healed at 1 year (with prior intervention)	>80% limb salvage at 1 year (both groups)	Mean ~2 years	p=0.019 for wound healing
<b>J. Vouillarmet et al., 2016</b>	Ulcer-healing rate	46% to 91% at 1 year	Not mentioned	1 year	Not specified
<b>Thomas Collins et al., 2024</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not specified
<b>M. Sabry et al., 2023</b>	Wound healing rate and time	With PAR: 89%, 92 days; Without PAR: 61%, 143 days	Not mentioned	Not mentioned	Not specified

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>Rongzhi Wen et al., 2023</b>	Reduction of trauma area	Study group 89.64% vs Routine group 70.11%	Amputation: 0 in study group vs 3 in routine group	At least 6 months	p<0.05 for significant findings
<b>M. E. Yamany et al., 2020</b>	Time to complete healing	Complete PAA: 9 weeks; No PAA: 29.2 weeks	Not mentioned	6 months	p=0.001 for healing times
<b>Keisuke Miyake et al., 2024</b>	Complete wound healing	78/117 limbs healed within 6 months	Not mentioned	6 months	Non-visualized perfusion to wounds OR 4.34 (p=0.0021)
<b>B. Vijaynagar et al., 2019</b>	Not mentioned	Not mentioned	Major limb amputation rate dropped from 0.83 to 0.44 per 1000	Not mentioned	Not specified

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>M. N. Bouayed et al., 2019</b>	Total healing	Average 5 months; shorter with EGF	Primary limb salvage 88%; secondary 55.7%	41 months	Not specified
<b>Pam Chen et al., 2024</b>	Complete wound healing, time to healing	Variable, often no significant difference vs standard care	Amputation rates often not significantly different	Varies (e.g., 12-24 weeks)	Not specified
<b>J. Brownrigg et al., 2013</b>	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not specified
<b>M. Doyle et al., 2020</b>	Healing rates (optimal, delayed, failure)	Not specified	76.8% amputation-free survival at 1 year	1 year	p=0.037 for timing of amputation $\geq 30$ days
<b>Alexander T. Hong et al., 2025</b>	Nonhealing ulcers	Not specified	Frailty development associated with revascularization procedures	12 months	OR for frailty dev. (revasc.): 9.09 (95% CI 2.30-45.34)

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>N. Troisi et al., 2021a</b>	Wound healing	62.5% at 6 months	Not mentioned	6 months	No significant association between time-density curves & TcPO <sub>2</sub>
<b>Fengjie Tang et al., 2023</b>	Wound healing	71.4% healed within 12 weeks	1 major, 9 minor amputations	12 weeks	Not specified
<b>Rushabh A Parekh et al., 2024</b>	Ulcer healing outcome	80% showed improvement	Not mentioned	3 months	Significant association between ABPI/TBI and Doppler findings
<b>R. Jarosiková et al., 2025</b>	Healing, amputation	SAD associated with non-healing after 6 months	SAD associated with amputation risk after 6 months	6 months	p=0.043 for association after 6 months

Citation	Primary Outcome Measure	Healing Rate/Time	Secondary Outcomes	Follow-up Duration	Key Statistical Results
<b>E. Iacopi et al., 2023</b>	Healing rate and time	Group A 80.4%, 67 days vs Group B 60.4%, 134 days	Not mentioned	Not mentioned	p=0.0021 for rate; p=0.020 for time
<b>Mwidimi Ndosi et al., 2017</b>	Healing incidence				

---

## DISCUSSION

---

This systematic review synthesizes a large and heterogeneous body of literature to address the association between pedal access intervention and radiologically measured wound healing in diabetic foot ulcers. The findings consistently and robustly support a positive and clinically significant association, confirming our primary hypothesis. The evidence demonstrates that successfully restoring pulsatile blood flow to the foot, particularly through the pedal arch, is a critical determinant of wound healing, as objectively measured by various imaging modalities.

### **The Critical Role of the Pedal Arch and Pedal Arch Revascularization (PAR)**

One of the most striking findings across multiple studies is the paramount importance of the pedal arch's integrity and patency. Troisi et al. (2018, 2017) and Ismail et al. (2020) provided foundational evidence showing that patients with a **complete pedal arch (CPA)** post-intervention have significantly better outcomes than those with an incomplete (IPA) or absent (APA) arch. This was not merely a statistical association but a profound clinical difference: CPA patients exhibited

dramatically higher healing rates (up to 93.3% vs. 52.6% for APA), substantially shorter healing times (3.5 vs. 5.7 months), and near-perfect 1-year limb salvage (100% vs. 68.4%). These findings were echoed by Ghweeba and Ghweeba (2022) and Abdelghaffar et al. (2023), further solidifying the CPA as a powerful prognostic indicator. The pedal arch serves as the final common pathway for blood delivery to the forefoot and digits. An open arch provides a low-resistance circuit that can perfuse the entire foot, whereas an occluded arch leaves the foot dependent on inadequate collaterals, perpetuating ischemia despite successful proximal intervention. This concept is elegantly illustrated by Lee et al. (2024), who showed that proximal revascularization itself can lead to a 24.1% improvement in complete pedal arch patency, directly correlating with improved healing (HR for failure with CPA: 0.40, P=0.039).

Building on this, studies focusing specifically on **Pedal Arch Revascularization (PAR)** confirmed its immense therapeutic value. Shahat et al. (2024) and Jung et al. (2019) demonstrated that successful PAR was associated with healing rates exceeding 75% and a dramatic reduction in major amputation (from 40.9% to 5.1% in the Shahat study). The odds ratio for failure of healing with unsuccessful PAR was a staggering 21.64, underscoring that failure to restore flow through the arch is a near-catastrophic event (Shahat et al., 2024). Nakama et al. (2017) in the RENDEZVOUS registry also confirmed this, with pedal artery angioplasty (PAA) resulting in a 57.5% healing rate versus 37.3% in the no-PAA group. These studies collectively argue that when infra-popliteal disease extends into the foot, intervention cannot stop at the ankle; it must address the pedal arch itself to achieve optimal outcomes.

### **Angiosome-Guided Revascularization: Direct vs. Indirect Flow**

The angiosome concept, which posits that specific areas of the foot are perfused by specific source arteries, has gained traction as a strategy to guide revascularization. The evidence from this review suggests that **direct revascularization (DR)** of the artery feeding the ulcer's angiosome is superior to **indirect revascularization (IR)** via collaterals. Khor and Price (2017) and Söderström et al. (2013) both reported a near-identical hazard ratio of 1.97 (95% CI, 1.34-2.90, P=0.001) for

wound healing with DR compared to IR. Chae and Shin (2016), in a meta-analysis, also found a significantly higher odds ratio for wound healing (3.290,  $p < 0.001$ ) with angiosome-targeted angioplasty.

However, this concept is nuanced. Troisi et al. (2017) made a critical observation, suggesting that the quality of the pedal arch (CPA vs. IPA/APA) might be a more important predictor of success than the directness of revascularization. They posited that a CPA can effectively turn an IR into a functional DR by providing robust collaterals, while a poor arch may render even a direct revascularization ineffective. This highlights the interconnectedness of these concepts and suggests that the ultimate goal should be to achieve a CPA, whether through DR of a specific artery or by improving overall inflow to the point that the arch can be pressurized. The work of Alexandrescu et al. (2019) supports this by showing that wound-targeted revascularization (WTR) in a "best endovascular effort" approach led to superior healing rates and times compared to non-targeted IR, even in a real-world, complex patient cohort.

### **The Emergence of Novel, Non-Invasive Radiological Markers**

A significant theme in the recent literature is the validation of non-invasive or minimally invasive imaging techniques to assess perfusion and predict healing. **Pedal Acceleration Time (PAT)**, measured by duplex ultrasound, has emerged as a particularly promising tool. PAT is the time it takes for blood flow in a pedal artery to reach its peak systolic velocity; a prolonged PAT indicates significant proximal obstruction. Sommerset et al. (2020) and Karmy-Jones et al. (2024) demonstrated that PAT correlates strongly with wound healing, with an 81.5% healing rate and limb salvage predicted by post-procedural PAT values. Dell and Shafique (2021) provided a practical threshold, showing that 10/11 ulcers with a PAT  $< 180$ ms healed. This offers a powerful, repeatable, and non-invasive bedside tool to not only diagnose PAD but also to triage patients, assess response to intervention, and predict outcomes (Pinelo et al., 2024; Silva et al., 2025; Elyamany et al., 2025). Its utility is further validated by its integration into studies examining intraprocedural hemodynamics (Spiliopoulos et al., 2023) and long-term outcomes (Hart et al., 2024).

### **The International Journal of Medical Science and Health Research**

Other novel techniques include **2D perfusion angiography**, which can generate time-density curves to quantify tissue perfusion. Troisi et al. (2021a) explored this in patients undergoing femoro-popliteal intervention, but found no significant association with TcPO<sub>2</sub> changes, suggesting that improvements in proximal flow may not always translate to distal microvascular changes in complex patients. This underscores the need for direct assessment of foot-level perfusion. Furthermore, **MAC (Medial Arterial Calcification) scores** from plain radiographs have been investigated as a prognostic marker. Skolnik et al. (2021) found an association between MAC score and major adverse limb events (HR 1.09; 95% CI 1.01-1.18), while Jarosiková et al. (2025) linked "small artery disease" (SAD/MAC) to non-healing after PTA. These findings suggest that the severity of calcification, a common finding in diabetic PAD, can independently predict poor outcomes, possibly by impairing the vasodilatory capacity and compliance of the arteries (Carmena-Pantoja et al., 2021).

### **Clinical Outcomes and the Importance of Multidisciplinary Care**

The ultimate goal of revascularization is not just a healed wound, but a functional, pain-free limb. The reviewed studies consistently show that successful revascularization translates to superior **limb salvage rates**. Caetano et al. (2020) reported a major amputation rate of only 3.9% in patients with successful revascularization versus 24.1% in those where it failed ( $p < 0.0001$ ). Brechow et al. (2013) also showed that addressing PAD through revascularization improves major amputation rates in complex patients. Elgzyri et al. (2014) provided critical evidence on the importance of **timing**, showing that early revascularization ( $< 8$  weeks from presentation) is significantly associated with higher healing probability ( $p < 0.001$ ). This highlights the need for rapid access to vascular specialists, as advocated by Vijaynagar et al. (2019) and Tang et al. (2023) with their "rapid access" and "DREAM" clinic models, respectively.

Furthermore, the studies underscore that revascularization is just one part of a complex equation. Patient factors such as **glycemic control** (Dutta et al., 2021; Fesseha et al., 2018), **frailty** (Hong et al., 2025), **infection and osteomyelitis** (Iacopi et al., 2023; Tardáguila-

García et al., 2023), **renal disease** (M. Doyle et al., 2020), and **offloading** (Jason Zhang et al., 2024) are all powerful determinants of healing. This reinforces the absolute necessity of a **multidisciplinary team (MDT) approach** involving podiatrists, vascular surgeons, interventional radiologists, infectious disease specialists, and endocrinologists to optimize all aspects of patient care (Macfarlane et al., 2024; Meloni et al., 2021; S. H. Lu & McLaren, 2017).

### **Confounding Factors and Study Limitations**

Despite the consistency of the findings, several limitations and confounders must be considered when interpreting this body of evidence.

1. **Heterogeneity:** The most significant limitation is the profound heterogeneity across studies. This includes variability in patient populations (e.g., varying Wagner/UT grades, inclusion/exclusion of ESRD), interventions (type of procedure, target vessels, timing), outcome measures (clinical vs. radiological, definitions of healing), and follow-up durations. This makes direct comparison and quantitative synthesis (meta-analysis) challenging.
2. **Study Design:** The vast majority of studies are observational cohort studies (retrospective or prospective), which are susceptible to selection bias and unmeasured confounding. There is a notable lack of large, well-designed randomized controlled trials (RCTs) directly comparing different revascularization strategies. Systematic reviews by Forsythe et al. (2020), Hinchliffe et al. (2016), and Chuter et al. (2023) all acknowledge this as a major limitation of the field.
3. **Confounding Factors:** Many studies fail to adequately control for key confounders. For example, the impact of optimal medical therapy (antiplatelets, statins), smoking cessation, infection status, and wound care protocols is often not included in multivariate models. The presence of **osteomyelitis** is a particularly powerful confounder, as it can persist despite adequate perfusion and prevent wound healing (E. Iacopi et al., 2023; Aroa Tardáguila-García et al., 2023).

4. **Radiological Assessment Standards:** There is a lack of standardization in radiological assessments. Who performs the measurement (e.g., a blinded radiologist vs. the treating physician) and data on inter-observer reliability are rarely reported, introducing potential measurement bias. The definition of a "complete" pedal arch can also vary.
5. **Publication Bias:** Studies with positive findings are more likely to be published, potentially skewing the overall impression of an intervention's effectiveness.
6. **Generalizability:** Many studies have exclusion criteria (e.g., life expectancy <1 year, severe dementia, non-ambulatory status) that limit the applicability of findings to the "real-world" population of frail, multi-morbid patients often seen in clinical practice.

---

## CONCLUSION AND SUGGESTIONS

---

### Conclusion

This systematic review provides compelling evidence for a strong, positive, and clinically meaningful association between successful pedal access intervention and radiologically measured wound healing progression in diabetic foot ulcers. The key determinant of success is the restoration of robust, pulsatile blood flow to the foot, most effectively achieved by establishing or preserving a **complete pedal arch**. Pedal arch revascularization and angiosome-directed approaches are both effective strategies for achieving this goal. The integration of advanced, non-invasive radiological tools like **pedal acceleration time (PAT)** offers a paradigm shift, enabling objective patient assessment, procedural guidance, and outcome prediction. While the evidence base is robust in its consistency, it is largely derived from observational studies with significant heterogeneity. Nevertheless, the findings unequivocally support an aggressive revascularization strategy for ischemic DFUs, ideally delivered within a multidisciplinary framework and as early as possible in the patient's care pathway. Failure to address distal pedal disease leaves patients at a drastically elevated risk of non-healing, major amputation, and loss of independence.

## Suggestions for Future Research and Clinical Practice

1. **Standardization of Outcomes:** The field would greatly benefit from a core outcome set for DFU research. This should include standardized definitions of wound healing (e.g., time to complete epithelialization), radiological measures (e.g., a universally accepted classification for pedal arch patency and PAT thresholds), and clinical endpoints (e.g., major adverse limb events). This would facilitate robust meta-analyses and cross-study comparisons.
2. **Need for Randomized Controlled Trials:** Well-designed, multicenter RCTs are urgently needed to compare different revascularization strategies head-to-head (e.g., PAR vs. angiosome-guided tibial intervention, endovascular-first vs. surgical bypass in suitable candidates). These trials should stratify patients based on pre-intervention pedal arch quality and use standardized, objective healing measures as the primary endpoint.
3. **Validation of Imaging Biomarkers:** Further prospective studies are needed to validate the predictive power of PAT, MAC scores, and perfusion angiography in diverse patient populations. Research should focus on establishing definitive, clinically actionable thresholds for these biomarkers to guide treatment decisions (e.g., "a PAT of >225ms should prompt immediate revascularization").
4. **Integration of Advanced Imaging into Clinical Pathways:** Healthcare systems should invest in training and equipment to make tools like duplex ultrasound with PAT capability a standard part of the vascular assessment for all patients with DFUs. This will allow for more precise patient selection and earlier intervention.
5. **Focus on Multidisciplinary Care:** The evidence overwhelmingly supports the MDT model. Healthcare institutions must prioritize and resource integrated foot care teams to ensure that revascularization is seamlessly combined with optimal offloading, infection management, glycemic control, and nutritional support.

6. **Addressing Confounders in Research:** Future studies must meticulously collect and account for key confounders, particularly the presence and treatment of osteomyelitis, glycemic control (HbA1c), nutritional status, and medication adherence. This will help isolate the true treatment effect of revascularization.

---

## REFERENCES

---

A. Brechow, Torsten Slesaczeck, D. Münch, T. Nanning, Hartmut Paetzold, U. Schwanebeck, S. Bornstein, and M. Weck. “Improving Major Amputation Rates in the Multicomplex Diabetic Foot Patient: Focus on the Severity of Peripheral Arterial Disease.” *Therapeutic Advances in Endocrinology and Metabolism*, 2013.

A. Caetano, Inês Conde Vasco, Filipe Veloso Gomes, N. Costa, J. H. Luz, E. Spaepen, A. Formiga, É. Coimbra, J. Neves, and T. Bilhim. “Successful Revascularization Has a Significant Impact on Limb Salvage Rate and Wound Healing for Patients with Diabetic Foot Ulcers: Single-Centre Retrospective Analysis with a Multidisciplinary Approach.” *Cardiovascular and Interventional Radiology*, 2020.

A. Hartemann-Heurtier, G. H. Van, J. Danan, F. Koskas, S. Jacqueminet, JL Golmard, and André Grimaldi. “Outcome of Severe Diabetic Foot Ulcers After Standardised Management in a Specialised Unit.” *Diabetes & Metabolism*, 2002.

A. Liakos, Paraskevi Liakopoulou, and A. Tsapas. “Cyclical Pressurized Topical Wound Oxygen Therapy Increased Healing of Refractory Diabetic Foot Ulcers.” *Annals of Internal Medicine*, 2020.

A. M. Mahon, C. MacGilchrist, Caroline McIntosh, and Timothy O'Brien. “Characterization of Patients with Diabetic Foot Disease Presenting to an Irish Podiatry Centre: Profiling Suitability for Entry to a Clinical Trial of Advanced Wound Therapeutics.” *Irish Journal of Medical Science*, 2017.

A. MacDonald, J. Brodell, J. Daiss, E. Schwarz, and I. Oh. “Evidence of Differential Microbiomes in Healing Versus Non-healing Diabetic Foot Ulcers Prior to and Following Foot Salvage Therapy.” *Journal of Orthopaedic Research*, 2019.

Aditya Dutta, A. Bhansali, and A. Rastogi. “Early and Intensive Glycemic Control for Diabetic Foot Ulcer Healing: A Prospective Observational Nested Cohort Study.” *International Journal of Lower Extremity Wounds*, 2021.

Ahmed Hossny, Mahmoud S. Eldesouky, and M. Abdellatif. “Angiosome Based Revascularization for Diabetic Foot Ulcer.” *International Surgery Journal*, 2019.

Alexander T. Hong, Ivan Y. Luu, Brandon Deras-Guerra, Sukgu M. Han, Laura Shin, Chia-Ding Shih, David G. Armstrong, and Tze-Woei Tan. “Association Between Frailty Progression and Clinical Outcomes in Patients with Diabetic Foot Ulcers.” *Surgery*, 2025.

Andreia Pinelo, Luís Loureiro, Joana Martins, Jill Sommerset, Rui Carvalho, and Rui Machado. “CORRELATION BETWEEN PEDAL ACCELERATION TIME AND TRANSCUTANEOUS OXYGEN PRESSURES - A PROGNOSTIC TOOL FOR WOUND HEALING IN THE DIABETIC FOOT POPULATION.” *Annals of Vascular Surgery*, 2024.

Andreia Pinelo, Maria Afonso, and Ivone Silva. “Comparative Outcomes of Targeted Versus Non-Targeted Angiosome Revascularization for Diabetic Foot Wounds Impact of Target Arterial Path on Wound Healing.” *Annals of Vascular Surgery*, 2024.

Aroa Tardáguila-García, F. Álvaro-Afonso, M. García-Madrid, M. López-Moral, I. Sanz-Corbalán, and J. Lázaro-Martínez. “Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis.” *Journal of Clinical Medicine*, 2023.

Aroa Tardáguila-García, Y. García-Álvarez, I. Sanz-Corbalán, M. López-Moral, R. Molines-Barroso, and J. Lázaro-Martínez. “Could X-Ray Predict Long-Term Complications in Patients with Diabetic Foot Osteomyelitis?” *Advances in Skin & Wound Care*, 2022.

Arthur C Yelland, C. Meace, P. Knighton, N. Holman, S. Wild, Julie Michalowski, B. Young, and W. Jeffcoate. "Impact of Case-mix Adjustment on Observed Variation in the Healing of Diabetic Foot Ulcers at 12 Weeks Using Data from the National Diabetes Foot Care Audit of England and Wales: A Cohort Study." *Diabetic Medicine*, 2022.

Asmat Burhan, F. Arofiati, Vanessa Abreu da Silva, and Septian Mixrova Sebayang. "Effect of Ankle Brachial Index (Abi) and Compression Therapy on Diabetic Foot Ulcer Healing." *Current Diabetes Reviews*, 2023.

B. Aliahmad, Aye N. Tint, Sridhar Poosapadi Arjunan, P. Rani, D. Kumar, Julie Miller, J. Zajac, Gayathiri Wang, and E. Ekinci. "Is Thermal Imaging a Useful Predictor of the Healing Status of Diabetes-Related Foot Ulcers? A Pilot Study." *Journal of Diabetes Science and Technology*, 2018.

B. Dong, Xixu Wang, Wei Wang, B. Hong, Jue Wang, Heng Wang, and Y. Gu. "Effect of Percutaneous Endovascular Angioplasty Combined with Negative Pressure Drainage on the "One-Stop" Treatment of Ischemic Diabetic Foot Ulcer." *Annals of Vascular Surgery*, 2022.

B. Lin, Chang-Cheng Chang, Yuan-Hsi Tseng, Jhe-Ruei Li, Yunling Peng, and Yao-Kuang Huang. "Using Wireless Near-Infrared Spectroscopy to Predict Wound Prognosis in Diabetic Foot Ulcers." *Advances in Skin & Wound Care*, 2020.

B. Vijaynagar, Terri-Ann Russell, Andrew Hornby, P. Grannon, M. Pierides, T. DeHaro, M. Mousley, et al. "Rapid Access Vascular Clinics for Patients with Diabetes – A Multidisciplinary Approach Saves Legs," 2019.

B. Y. C. Khor, and P. Price. "The Comparative Efficacy of Angiosome-Directed and Indirect Revascularisation Strategies to Aid Healing of Chronic Foot Wounds in Patients with Co-Morbid Diabetes Mellitus and Critical Limb Ischaemia: A Literature Review." *Journal of Foot and Ankle Research*, 2017.

Betiel K. Fesseha, C. Abularrage, Kathryn F. Hines, R. Sherman, P. Frost, Susan J. Langan, J. Canner, et al. "Association of Hemoglobin A1c and Wound Healing in Diabetic Foot Ulcers." *Diabetes Care*, 2018.

Bhavani Prasad Mahindrakar, A. Goswami, Farhanul Huda, Manisha Naithani, and S. Basu. "Wound pH and Surface Temperature as a Predictive Biomarker of Healing in Diabetic Foot Ulcers." *International Journal of Lower Extremity Wounds*, 2023.

C. Gazzaruso, P. Gallotti, A. Pujia, T. Montalcini, A. Giustina, and A. Coppola. "Predictors of Healing, Ulcer Recurrence and Persistence, Amputation and Mortality in Type 2 Diabetic Patients with Diabetic Foot: A 10-Year Retrospective Cohort Study." *Endocrine*, 2020.

C. Hicks, J. Canner, N. Mathioudakis, Ronald L. Sherman, Kathryn F. Hines, Christopher Lippincott, J. Black, and C. Abularrage. "Neighborhood Socioeconomic Disadvantage Is Not Associated with Wound Healing in Diabetic Foot Ulcer Patients Treated in a Multidisciplinary Setting." *Journal of Surgical Research*, 2018.

Chang Sik Shin, and Kwon Cheol Yoo. "Predictive Factors of Wound Healing and Limb Salvage After Successful Below-the-Knee Endovascular Angioplasty in Patients with Diabetic Foot Ulcer: A Retrospective Study." *Medicina*, 2025.

D. Armstrong, D. Orgill, R. Galiano, P. Glat, J. Kaufman, M. Carter, and Charles M Zelen. "An Observational Pilot Study Using a Purified Reconstituted Bilayer Matrix to Treat Non-healing Diabetic Foot Ulcers." *International Wound Journal*, 2020.

D. Lowry, and A. Tiwari. "Changes in Microcirculation Following Percutaneous Angioplasty in Patients with Diabetic Foot Ulcers." *European Journal of Vascular and Endovascular Surgery*, 2018.

D. Margolis, L. Allen-Taylor, O. Hoffstad, and J. Berlin. “Diabetic Neuropathic Foot Ulcers: The Association of Wound Size, Wound Duration, and Wound Grade on Healing.” *Diabetes Care*, 2002.

———. “Healing Diabetic Neuropathic Foot Ulcers: Are We Getting Better?” *Diabetic Medicine*, 2005.

D. Wukich, Katherine M Raspovic, Kimberlee B. Hobizal, and Bedda L. Rosario. “Radiographic Analysis of Diabetic Midfoot Charcot Neuroarthropathy With and Without Midfoot Ulceration.” *Foot & Ankle International*, 2014.

Danlan Pu, Xiaotian Lei, Weiling Leng, Yanling Zheng, Liu Chen, Z. Liang, Bing Chen, and Qinan Wu. “Lower Limb Arterial Intervention or Autologous Platelet-Rich Gel Treatment of Diabetic Lower Extremity Arterial Disease Patients with Foot Ulcers.” *Annals of Translational Medicine*, 2019.

David A. Reiter, Scott J Edwards, N. Soleimanmanesh, Jesica Flores, Nataliya Y. Chaudhry, G. Santamarina, Marcos C. Schechter, and M. Fayfman. “500-P: Assessment of MRI Markers of Foot Perfusion and Microvascular Function in People with Diabetic Foot Ulcers (DFU) and Wound Healing.” *Diabetes*, 2025.

Dr. Madhuri Jain, Dr. Ranjeet Kamble, and Dr. Vineeth Kumar. “Prospective Observational Study to Note the Clinical Outcomes and Explore Prognostic Factors Related to Ulcer Healing in Patients with Diabetic Foot.” *International Journal of Surgery Science*, 2022.

E. Iacopi, Francesco Giangreco, A. Leonildi, Valerio Ortenzi, Lorenzo ROBERTO SUARDI, L. Pieruzzi, C. Goretti, et al. “101-OR: Systematic Intraoperative Bone Sampling Increases Healing Chances in Diabetic Foot Osteomyelitis.” *Diabetes*, 2023.

E. Saricilar, Raleene Gatmaitan, Kiraati Patel, and Mark Yang. “The Role of Targeted Infra-Popliteal Endovascular Angioplasty to Treat Diabetic Foot Ulcers Using the Angiosome Model: A Systematic Review.” *Vascular and Endovascular Review*, 2023.

Eduardo Silva, Joana Iglésias, Pedro Lima, Luís F. Antunes, and Manuel Fonseca. “Using Pedal Acceleration Time To Predict Ischemic Wound Healing In Diabetic Patients.” *Portuguese Journal of Cardiac Thoracic and Vascular Surgery*, 2025.

F. Álvaro-Afonso, Y. García-Álvarez, E. García-Morales, Sebastián Flores-Escobar, Luis de Benito-Fernández, Jesús Alfayate-García, J. P. Sánchez-Ríos, et al. “Determining the Best Noninvasive Test for Peripheral Arterial Disease Diagnosis to Predict Diabetic Foot Ulcer Healing in Patients Following Endovascular Revascularization.” *Healthcare*, 2024.

F. Game, J. Apelqvist, C. Attinger, A. Hartemann, R. Hinchliffe, M. Löndahl, P. Price, and W. Jeffcoate. “Effectiveness of Interventions to Enhance Healing of Chronic Ulcers of the Foot in Diabetes: A Systematic Review.” *Diabetes/Metabolism Research Reviews*, 2016.

F. Game, and W. Jeffcoate. “How to Assess the Quality of Clinical Trials for Diabetic Foot Ulcer Therapies,” 2020.

Fengjie Tang, Siti Nurfarahdillah Binte Abdul Razak, Jerilyn Xiling Tan, E. Choke, and S. Zainudin. “Fast-Access Multidisciplinary Approach to Management of Diabetic Foot Ulcers: The Diabetic Rapid Evaluation and Lower Limb Amputation Management (DREAM) Clinic.” *Clinical Medicine Insights: Endocrinology and Diabetes*, 2023.

G. Andros. “Diagnostic and Therapeutic Arterial Interventions in the Ulcerated Diabetic Foot.” *Diabetes/Metabolism Research Reviews*, 2004.

García-Sáenz Mc, and Lund Kt. “The Beneficial Effect of Motorised Ankle Dorsiflexion on the Healing of Diabetic Foot Ulcers.” 2004.

H. Elghazaly, Theodore Howard, Sharan Sanjay, Omer Mohamed, V. Sounderajah, Zaheer Mehar, Alun H Davies, U. Jaffer, and P. Normahani. "Evaluating the Prognostic Performance of Bedside Tests Used for Peripheral Arterial Disease Diagnosis in the Prediction of Diabetic Foot Ulcer Healing." *BMJ Open Diabetes Research & Care*, 2023.

H. Jung, Y. Ko, Sung-Jin Hong, C. Ahn, Jung-Sun Kim, Byeong-Keuk Kim, D. Choi, M. Hong, and Y. Jang. "Impact of Endovascular Pedal Artery Revascularisation on Wound Healing in Patients With Critical Limb Ischaemia." *European Journal of Vascular and Endovascular Surgery*, 2019.

H. Mohafez, S. A. Ahmad, M. Hadizadeh, S. Moghimi, S. Roohi, M. Marhaban, M. Saripan, and S. Rampal. "Quantitative Assessment of Wound Healing Using High-frequency Ultrasound Image Analysis." *Skin Research and Technology*, 2018.

Hanan Ansari, Intan Habibi, and Munafirah Munafirah. "Exploring the Determinants of Diabetic Foot Ulcer Healing: A 12-Month Longitudinal Study." *Journal of Wound Research and Technology*, 2025.

Hendri, R. Suhartono, Aria Kekalih, J. R. Adriani, and M. Faruk. "Healing Rate Comparison of Revascularized and Non-Revascularized Diabetic Foot Ulcers with Peripheral Arterial Disease." *Surgery Open Science*, 2023.

Hsi-An Yang, Ren-Jun Hsu, Wun-Long Jheng, Feng-Ju Weng, and Jian-Jr Lee. "Comparative Efficacy of Regenerative Therapies for Diabetic Foot Ulcers." *Annals of Plastic Surgery*, 2025.

Ivan Jozic. "524-P: Diabetic Foot Ulcer Wound Dressings May Serve as an Untapped Source of Predictive and Monitoring Biomarkers of Healing Outcome." *Diabetes*, 2024.

Ivan Y. Luu, Alexander T. Hong, Ashton Lee, Juan C. Arias, Chia-Ding Shih, David G. Armstrong, and Tze-Woei Tan. "Improved Diabetic Foot Ulcer Outcomes in Medicaid Beneficiaries with Podiatric Care Access." *Diabetology*, 2024.

Ivana Roth-Albin, S. Mai, Zeeshan Ahmed, Ji Cheng, K. Choong, and Perry V. Mayer. “Outcomes Following Advanced Wound Care for Diabetic Foot Ulcers: A Canadian Study.” *Canadian Journal of Diabetes*, 2017.

J. A. Cheong, Jessica M. Irvine, Shane Roesemann, Anna Nora, Courtney E. Morgan, Christopher Daniele, Lindsay R. Kalan, and M. Brennan. “Ankle Brachial Indices and Anaerobes: Is Peripheral Arterial Disease Associated with Anaerobic Bacteria in Diabetic Foot Ulcers?” *Therapeutic Advances in Endocrinology and Metabolism*, 2022.

J. Apelqvist, T. Elgzyri, J. Larsson, M. Löndahl, P. Nyberg, and J. Thörne. “Factors Related to Outcome of Neuroischemic/Ischemic Foot Ulcer in Diabetic Patients.” *Journal of Vascular Surgery*, 2011.

J. Brownrigg, J. Apelqvist, K. Bakker, N. Schaper, and R. Hinchliffe. “Evidence-Based Management of PAD & the Diabetic Foot.” *European Journal of Vascular and Endovascular Surgery*, 2013.

J. Brownrigg, N. Schaper, and R. Hinchliffe. “Diagnosis and Assessment of Peripheral Arterial Disease in the Diabetic Foot.” *Diabetic Medicine*, 2015.

J. Lindberg. “Predicting Clinical Outcomes in a Diabetic Foot Ulcer Population Using Fluorescence Imaging.” *Advances in Skin & Wound Care*, 2021.

J. Reekers. “Interventional Radiology in the Diabetic Lower Extremity.” *The Medical Clinics of North America*, 2013.

———. “The Role of Interventional Radiology in the Treatment of Arterial Diabetic Foot Disease.” *Cardiovascular and Interventional Radiology*, 2016.

J. Vouillarmet, O. Bourron, J. Gaudric, P. Lermusiaux, A. Millon, and A. Hartemann. “Lower-Extremity Arterial Revascularization: Is There Any Evidence for Diabetic Foot Ulcer-Healing?” *Diabetes & Metabolism*, 2016.

Jacqueline N. McNulty, Brandon J. Lewis, J. Fontaine, April Rose, M. Gómez, L. Meneghini, U. Gunasekaran, and M. S. Ruiz. “Diabetes Foot Wound Healing—A Collaborative Approach.” *Diabetes*, 2018.

Jarrold M. Shapiro, and A. Nouvong. “Assessment of Microcirculation and the Prediction of Healing in Diabetic Foot Ulcers,” 2011.

Jason Chow, Sahand Imani, Isuri Kavisinghe, R. Mittal, and Brian Martin. “Definitive Single-stage Surgery for Treating Diabetic Foot Osteomyelitis: A Protocolized Pathway Including Antibiotic Bone Graft Substitute Use.” *ANZ Journal of Surgery*, 2024.

Jason Zhang, M. Sadek, Louis Iannuzzi, Caron Rockman, Karan Garg, Allison Taffet, Molly Ratner, et al. “Total Contact Casting Remains an Effective Modality for Treatment of Diabetic Foot Ulcers.” *Vascular and Endovascular Surgery*, 2024.

Jasper A Sung, Seema Gurung, Teresa Lam, Shehzi Yusaf, M. Vicaretti, L. Begg, N. Cheung, S. Padmanabhan, and C. Girgis. “A 'Speed-Dating' Model of Wound Care? Rapid, High-Volume Assessment of Patients With Diabetes in a Multidisciplinary Foot Wound Clinic.” *Experimental and Clinical Endocrinology & Diabetes*, 2020.

Jennifer Skolnik, R. Weiss, Andrew J. Meyr, Ravi V Dhanisetty, E. Choi, Matthew Cunningham-Hill, Daniel J. Rubin, and L. Oresanya. “Evaluating the Impact of Medial Arterial Calcification on Outcomes of Infrageniculate Endovascular Interventions for Treatment of Diabetic Foot Ulcers.” *Vascular and Endovascular Surgery*, 2021.

Jessica M. Eager, Juan F Cortes-Troncoso, Lindsay R Kalan, Amy Campbell, Amit Rao, Michael S Weingarten, Elizabeth A Grice, et al. “Differential Gene Expression in Healing and Non-Healing Diabetic Foot Ulcers and Discovery of Novel Ratiometric Biomarker to Predict Healing Outcome.” *Wound Repair and Regeneration*, 2025.

Jill Sommerset, Beejay Feliciano, R. Karmy-Jones, Yolanda Vea, Matthew R. Dally, and Desarom Teso. “Duplex Ultrasound Defined Angiosome With the Use of Pedal Acceleration Time as a Predictor to Wound Healing,” 2020.

Jiyong Ahn, Alexandra F. Flaherty, Yoochang Kim, L. Bejarano-Pineda, C. DiGiovanni, S. Ashkani-Esfahani, and G. Waryasz. “Efficacy of 3D Wound Assessment in Predicting Granulation Tissue Velocity Following Negative Pressure Wound Therapy in Diabetic Foot Ulcers.” *Foot & Ankle Orthopaedics*, 2024.

Jiyong Ahn, and Alexandra Flaherty. “Utility of 3D Wound Assessment in Monitoring Granulation Tissue Velocity Following Negative-Pressure Wound Therapy in Diabetic Foot Ulcers.” *Foot & Ankle International*, 2025.

Jon C. Henry, Auréline Boitet, Abhisekh Mohaptra, E. Avgerinos, R. Chaer, M. Makaroun, S. Leers, and E. Hager. “Prior Endovascular Intervention Is Not Detrimental to Pedal Bypasses for Ischemia,” 2016.

Junpeng Liu, Xingchen Yao, Ziyu Xu, Yue Wu, Fuchun Pei, Lin Zhang, Meng Li, Ming Shi, Xin-Ru Du, and Hui Zhao. “Modified Tibial Cortex Transverse Transport for Diabetic Foot Ulcers with Wagner Grade  $\geq$  II: A Study of 98 Patients.” *Frontiers in Endocrinology*, 2024.

K. Chae, and J. Shin. “Is Angiosome-Targeted Angioplasty Effective for Limb Salvage and Wound Healing in Diabetic Foot? : A Meta-Analysis.” *PLoS ONE*, 2016.

K. Claesson, T. Kölbel, and S. Acosta. “Role of Endovascular Intervention in Patients with Diabetic Foot Ulcer and Concomitant Peripheral Arterial Disease.” *International Angiology*, 2011.

K. Dell, and S. Shafique. “Evaluation of Healing Potential in Diabetic Foot Ulcer With Pedal Acceleration Time.” *Journal of Vascular Surgery*, 2021.

K. Marmagkiolis, Partha Sardar, J. Mustapha, M. Montero-Baker, Konstantinos Charitakis, C. Iliescu, and D. Feldman. “Transpedal Access for the Management of Complex Peripheral Artery Disease.” *The Journal of Invasive Cardiology*, 2017.

K. Spanos, V. Saleptsis, A. Athanasoulas, C. Karathanos, A. Bargiota, P. Chan, and A. Giannoukas. “Factors Associated With Ulcer Healing and Quality of Life in Patients With Diabetic Foot Ulcer.” *Angiology*, 2017.

Kaitlyn K Rogers, Ammar Rashied, M. Schechter, and M. Fayfman. “515-P: Study to Evaluate the Relationship Between Inpatient Glycemic Control as Measured by CGM and Wound Healing in Patients Admitted for Diabetic Foot Ulcer (DFU).” *Diabetes*, 2023.

Keisuke Miyake, Shinsuke Kikuchi, D. Uchida, Tsutomu Doita, Shigeru Miyagawa, and Nobuyoshi Azuma. “The Impact of Angiographic Pedal Circulation Status on Wound Healing in Chronic Limb-Threatening Ischemia After Bypass Surgery.” *Journal of Vascular Surgery*, 2024.

L. Prompers, N. Schaper, J. Apelqvist, M. Edmonds, E. Jude, D. Mauricio, L. Uccioli, et al. “Prediction of Outcome in Individuals with Diabetic Foot Ulcers: Focus on the Differences Between Individuals with and Without Peripheral Arterial Disease. The EURODIALE Study.” *Diabetologia*, 2008.

L. Ribu, K. Birkeland, B. Hanestad, T. Moum, and T. Rustøen. “A Longitudinal Study of Patients with Diabetes and Foot Ulcers and Their Health-Related Quality of Life: Wound Healing and Quality-of-Life Changes.” *Journal of Diabetes and Its Complications*, 2008.

Limi Lee, Stephen E Thwaites, Mitra Rahmatzadeh, Erwin Yii, Kevin Yoong, and Ming Yii. “PROXIMAL ARTERIAL INFLOW REVASCULARIZATION IMPROVES PEDAL ARCH QUALITY AND ITS IMPACT ON ISCHAEMIC DIABETIC FOOT ULCER HEALING.” *Annals of Vascular Surgery*, 2024.

Lucia Bubulac, I. Gheorghe, Elisabeth Ungureanu, C. Bogdan-Andreescu, Cristina-Crenguța Albu, C. Gheorghe, Ovidiu Mușat, Irina Anca Eremia, C. A. Panea, and Alexandru Burcea. “Promoting Re-Epithelialization in Diabetic Foot Wounds Using Integrative Therapeutic Approaches.” *Bioengineering*, 2025.

M. DeSanto, Luke Weber, Emmanuel Nageeb, Kyle A Petersen, and J. Junko. “An Orthopaedist’s Review of Diabetic Foot Wounds and Osteomyelitis,” 2020.

M. Doyle, G. Hastings, M. Dontsi, M. Ishibashi, M. Weintraub, and Jason D. Pollard. “The Correlation of the Trans-Atlantic Inter-Society Consensus Classification to Outcomes of Pedal Amputations.” *Journal of Foot and Ankle Surgery*, 2020.

M. Doyle, G. Hastings, M. Dontsi, Shontal Behan Dionisopoulos, L. Kane, and Jason D. Pollard. “The Effects of Endovascular Timing and In-Line Flow on the Success of Pedal Amputations.” *Journal of Foot and Ankle Surgery*, 2020.

M. E. Yamany, Hatem Mohamed, M. Boulos, and Sherif A. Raffat. “Impact of Endovascular Pedal Arteries Revascularization on Wound Healing in Patients with Critical Limb Ischemia,” 2020.

M. Fujii, H. Terashi, K. Yokono, and D. Armstrong. “The Degree of Blood Supply and Infection Control Needed to Treat Diabetic Chronic Limb-Threatening Ischemia with Forefoot Osteomyelitis.” *Journal of the American Podiatric Medical Association (Print)*, 2021.

M. Ghweeba, and Mayada Ghweeba. “Evaluation of Endovascular Pedal Arch Revascularization on Clinical Results and Tissue Healing in Diabetic Foot Patients with Lower Limb Ischemia.” *Medicine Updates*, 2022.

M. Meloni, J. Lázaro-Martínez, R. Ahluwalia, B. Bouillet, V. Izzo, Michela Di Venanzio, E. Iacopi, et al. “Effectiveness of Fast-Track Pathway for Diabetic Foot Ulcerations.” *Acta Diabetologica*, 2021.

M. N. Bouayed, and S. Benallal. “LEA 9. Revascularization and Growth Factor Injection: It Is Effective for Healing of Foot Ulcers.” *Journal of Vascular Surgery*, 2019.

M. Sabry, A. Shaker, and Hany A. Mohamed. “Effect of Endovascular Revascularization of Pedal Artery on Healing of the Wound in Patients with Chronic Limb-Threatening Ischemia.” *The Egyptian Journal of Surgery*, 2023.

M. Söderström, A. Albäck, F. Biancari, K. Lappalainen, M. Lepäntalo, and M. Venermo. “Angiosome-Targeted Infrapopliteal Endovascular Revascularization for Treatment of Diabetic Foot Ulcers.” *Journal of Vascular Surgery*, 2013.

Mariyam Iqbal, Iqra Imtiaz, Zahra Saghir, Aman Fatima, Fatima Javed, Maham Iqbal, and Muhammad Nauman Shahid. “Comparative Outcomes of Conservative Surgery Versus Early Surgical Intervention in Diabetic Foot Ulcers.” *DEVELOPMENTAL MEDICO-LIFE-SCIENCES*, 2024.

Marta Carmena-Pantoja, F. Álvaro-Afonso, E. García-Morales, Y. García-Álvarez, Aroa Tardáguila-García, and J. Lázaro-Martínez. “The Influence of Arterial Calcification on Clinical Outcomes in Patients with Diabetic Foot Ulcer Complicated by Osteomyelitis Treated by Surgery.” *International Journal of Lower Extremity Wounds*, 2021.

Martin C. Robson, D. Hill, Matthew E. Woodske, and David L. Steed. “Wound Healing Trajectories as Predictors of Effectiveness of Therapeutic Agents.” *Archives of Surgery*, 2000.

Michael Rouse, Qingwen Kawaji, Darshan Randhawa, Jason Chin, R. Vallabhaneni, and Jason Crowner. “Intra-Operative Pedal Pressure Changes Offers Another Quantitative Assessment For Revascularization.” *Annals of Vascular Surgery*, 2024.

Mohamed Elyamany, Hatem Alaa Mohamed Kamal, Hussien Mohamed, Ibrahim S. Ali, and M. M. Kamel. “A Prospective Study on Patients with Peripheral Chronic Limb Ischemia: Assessment of

Pedal Acceleration Time Pre and Post Revascularization.” *The Egyptian Journal of Hospital Medicine*, 2025.

Mohamed Fathy Abdelghaffar, A. M. Salem, Khaled Abdelsattar El dieb, and Moataz Ashraf Saleh Mohamed. “Is Inframallolar Angioplasty Effective for Wound Healing in Patients with Critical Lower Limb Ischemia and Tibial Only Disease?” *The Quarterly Journal of Medicine*, 2023.

Mohammed Shahat, Ahmed Hassan, Mostafa S Khalil, A. Taha, and Ahmed Elbadawy. “Exploring the Other Side of the River: Early and Midterm Outcomes of Endovascular Pedal Arch Revascularization in Patients with Chronic Limb-Threatening Ischemia.” *Journal of Endovascular Therapy*, 2024.

Mwidimi Ndosu, A. Wright-Hughes, S. Brown, M. Backhouse, Benjamin A Lipsky, M. Bhogal, C. Reynolds, et al. “Prognosis of the Infected Diabetic Foot Ulcer: A 12-month Prospective Observational Study.” *Diabetic Medicine*, 2017.

N. Akhtar, M. I. Anjum, S. Ullah, S. Nizami, Uzma Rasheed, and A. Rabbani. “Comparison of Angiosome Based Incision with Conventional Aggressive Debridement for the Treatment of Diabetic Foot Ulcers.” 2020.

N. Kontopodis, Emmanouhl Tavlas, G. Papadopoulos, D. Pantidis, A. Kafetzakis, G. Chalkiadakis, and C. Ioannou. “Effectiveness of Platelet-Rich Plasma to Enhance Healing of Diabetic Foot Ulcers in Patients With Concomitant Peripheral Arterial Disease and Critical Limb Ischemia.” *International Journal of Lower Extremity Wounds*, 2016.

N. Leone, Francesco Andreoli, M. Migliari, Federica Guerra, S. Sperduti, L. Casarini, R. Silingardi, and S. Gennai. “Clinical Outcomes and Characterisation of the Autologous Adipose Tissue Harvested With Superficial Enhanced Fluid Fat Injection Method for Treatment of Diabetic Foot Ulcer Undergoing Minor Amputation (SEFFIDiFA Trial).” *International Wound Journal*, 2025.

N. Santamaria, K. Carville, I. Ellis, and J. Prentice. “The Effectiveness of Digital Imaging and Remote Expert Wound Consultation on Healing Rates in Chronic Lower Leg Ulcers in the Kimberley Region of Western Australia,” 2004.

N. Troisi, Azzurra Guidotti, F. Turini, R. Lombardi, F. Falciani, C. Baggiore, S. Michelagnoli, and E. Chisci. “Influence of Pedal Arch Quality on 5-Year Survival and Limb Salvage in Patients with Diabetic Foot Ulcers Undergoing Peripheral Angiography.” *Vascular*, 2021.

N. Troisi, F. Turini, E. Chisci, L. Ercolini, Pierfrancesco Frosini, R. Lombardi, F. Falciani, C. Baggiore, R. Anichini, and S. Michelagnoli. “Impact of Pedal Arch Patency on Tissue Loss and Time to Healing in Diabetic Patients with Foot Wounds Undergoing Infrainguinal Endovascular Revascularization.” *Korean Journal of Radiology*, 2018.

———. “Pedal Arch Patency and Not Direct-Angiosome Revascularization Predicts Outcomes of Endovascular Interventions in Diabetic Patients with Critical Limb Ischemia.” *International Angiology*, 2017.

N. Troisi, S. Michelagnoli, S. Panci, S. Bacchi, Daniela Incerti, Luigi Lo Vecchio, G. Dedola, and E. Chisci. “Association of 2D Perfusion Angiography and Wound Healing Rate in Combined Femoro-Popliteal and Below-the-Knee Lesions in Ischemic Patients Undergoing Isolated Femoro-Popliteal Endovascular Revascularization.” *International Journal of Lower Extremity Wounds*, 2021.

Nantawan Koonalinthip, Pongbun Siwabanpakul, and Araya Jaroenarpornwatana. “The Effectiveness of Diabetic Foot Clinic in Prevention and Healing of Diabetic Foot Ulcers.” *The Foot*, 2021.

Nasibeh Vatankhah, Y. Jahangiri, G. Landry, R. Mclafferty, N. Alkayed, G. Moneta, and A. Azarbal. “Predictive Value of Neutrophil-to-lymphocyte Ratio in Diabetic Wound Healing.” *Journal of Vascular Surgery*, 2017.

Nicole K. Cates, Tammer Elmarsafi, Taylor J Bunka, Elliot T. Walters, Cameron M. Akbari, Caitlin S. Zarick, K. Evans, J. Steinberg, C. Attinger, and P. Kim. “Peripheral Vascular Disease Diagnostic Related Outcomes in Diabetic Charcot Reconstruction.” *Journal of Foot and Ankle Surgery*, 2019.

Nila N. Sari, Q. Ngo, N. Pah, R. Ogrin, Elif Ekinici, Akram Hourani, Barbara Polus, and D. Kumar. “Non-Invasive Imaging Techniques for Predicting Healing Status of Diabetic Foot Ulcers: A Ten-Year Systematic Review.” *Frontiers in Medical Technology*, 2025.

O. Galimov, V. O. Khanov, V. Ishmetov, T. R. Ibragimov, A. F. Biglova, and R. S. Sufiyarov. “Angiographic Therapies for Diabetic Foot Syndrome.” *Creative Surgery and Oncology*, 2021.

O. Oncul, Senol Yildiz, U. S. Gurer, E. Yeniiz, T. Qyrdedi, C. Top, Pervin Göçer, B. Akarsu, A. Çevikbaş, and Ş. Çavuşlu. “Effect of the Function of Polymorphonuclear Leukocytes and Interleukin-1 Beta on Wound Healing in Patients with Diabetic Foot Infections.” *Journal of Infection*, 2007.

Odette Hart, Khai Tuck Lee, S. Gormley, Bridget August, Grant Abbott, and M. Khashram. “Association of Pedal Acceleration Time With Healing and Amputation Free Survival in Patients With Ulceration and Gangrene.” *European Journal of Vascular and Endovascular Surgery*, 2024.

Olivia V. Waldman, Stephanie P. Hao, J. Houck, Nicolette J. Lee, J. Baumhauer, and I. Oh. “Operative Intervention Does Not Change Pain Perception in Patients With Diabetic Foot Ulcers.” *Clinical Diabetes*, 2020.

Osama A. Ismail, and Ahmed E. E. Ahmed. “Impact of Pedal Arch Revascularization on Clinical Outcomes of Diabetic Patients with Critical Limb Ischemia,” 2020.

P. Faries, V. Teodorescu, N. Morrissey, L. Hollier, and M. Marin. “The Role of Surgical Revascularization in the Management of Diabetic Foot Wounds.” *American Journal of Surgery*, 2004.

P. Ince, D. Kendrick, F. Game, and W. Jeffcoate. “The Association Between Baseline Characteristics and the Outcome of Foot Lesions in a UK Population with Diabetes.” *Diabetic Medicine*, 2007.

P. Lazzarini, G. Jarl, C. Gooday, V. Viswanathan, C. Caravaggi, D. Armstrong, and S. Bus. “Effectiveness of Offloading Interventions to Heal Foot Ulcers in Persons with Diabetes: A Systematic Review.” *Diabetes/Metabolism Research Reviews*, 2020.

P. Normahani, R. Agrawal, V. Sounderajah, P. Tsinaslanidis, P. Musonda, Zaheer Mehar, Katarzyna Powezka, V. Bravis, M. Aslam, and U. Jaffer. “Arterial Spectral Waveform Analysis in the Prediction of Diabetic Foot Ulcer Healing.” *Perfusion*, 2020.

P. Tappia, B. Hiebert, Rohan M. Sanjanwala, P. Komenda, C. Sathianathan, A. Arneja, and B. Ramjiawan. “A Novel Bathing Therapeutic Approach for Diabetic Foot Ulcers.” *Applied Sciences*, 2021.

Pam Chen, Nalini Campillo Vilorio, K. Dhatariya, William Jeffcoate, Ralf Lobmann, Caroline McIntosh, Alberto Piaggese, et al. “Effectiveness of Interventions to Enhance Healing of Chronic Foot Ulcers in Diabetes: A Systematic Review.” *Diabetes/Metabolism Research Reviews*, 2024.

Pamela Chen, Nalini Campillo Vilorio, K. Dhatariya, W. Jeffcoate, R. Lobmann, C. Mcintosh, A. Piaggese, et al. “Guidelines on Interventions to Enhance Healing of Foot Ulcers in People with Diabetes (IWGDF 2023 Update).” *Diabetes/Metabolism Research Reviews*, 2023.

Patricia M González-Villacorta, M. López-Moral, M. García-Madrid, E. García-Morales, Aroa Tardáguila-García, and J. Lázaro-Martínez. “Hyperspectral Imaging in the Healing Prognosis of Diabetes Related Foot Ulcers. A Systematic Review and Meta-Analysis.” *Microcirculation*, 2025.

R. Hinchliffe, George Andros, Jan Apelqvist, K. Bakker, S. Fiedrichs, J. Lammer, M. Lepäntalo, et al. “A Systematic Review of the Effectiveness of Revascularization of the Ulcerated Foot in

Patients with Diabetes and Peripheral Arterial Disease.” *Diabetes/Metabolism Research Reviews*, 2012.

R. Hinchliffe, J. Brownrigg, G. Andros, J. Apelqvist, E. Boyko, R. Fitridge, J. Mills, et al. “Effectiveness of Revascularization of the Ulcerated Foot in Patients with Diabetes and Peripheral Artery Disease: A Systematic Review.” *Diabetes/Metabolism Research Reviews*, 2016.

R. Jarosiková, Theodor Adla, Patrik Turza, M. Dubský, V. Wosková, D. Sojakova, Věra Lánská, and V. Fejfarová. “Small Artery Disease as a Predictor of Wound Healing in Patients with Diabetic Foot After Revascularization.” *International Journal of Lower Extremity Wounds*, 2025.

R. Snyder, and J. Hanft. “Diabetic Foot Ulcers--Effects on QOL, Costs, and Mortality and the Role of Standard Wound Care and Advanced-Care Therapies.” *Ostomy/Wound Management*, 2009.

R. Snyder, Matthew Cardinal, Damien Dauphinee, and J. Stavosky. “A Post-Hoc Analysis of Reduction in Diabetic Foot Ulcer Size at 4 Weeks as a Predictor of Healing by 12 Weeks.” *Ostomy/Wound Management*, 2010.

R. Somayaji, James A. Elliott, R. Persaud, Morgan Lim, Morgan Lim, L. Goodman, and R. Sibbald. “The Impact of Team Based Interprofessional Comprehensive Assessments on the Diagnosis and Management of Diabetic Foot Ulcers: A Retrospective Cohort Study.” *PLoS ONE*, 2017.

R. Warriner, R. Snyder, and Matthew Cardinal. “Differentiating Diabetic Foot Ulcers That Are Unlikely to Heal by 12 Weeks Following Achieving 50% Percent Area Reduction at 4 Weeks.” *International Wound Journal*, 2011.

Rachael O. Forsythe, J. Apelqvist, Edward J. Boyko, R. Fitridge, Joon P. Hong, K. Katsanos, Joseph L. Mills, et al. “Effectiveness of Revascularisation of the Ulcerated Foot in Patients with Diabetes and Peripheral Artery Disease: A Systematic Review.” *Diabetes/Metabolism Research Reviews*, 2020.

Rachael O. Forsythe, J. Apelqvist, Edward J. Boyko, R. Fitridge, Joon P. Hong, K. Katsanos, Joseph L. Mills, et al. "Performance of Prognostic Markers in the Prediction of Wound Healing or Amputation Among Patients with Foot Ulcers in Diabetes: A Systematic Review." *Diabetes/Metabolism Research Reviews*, 2020.

Rachael O. Forsythe, J. Apelqvist, Edward J. Boyko, R. Fitridge, Joon P. Hong, Konstantinos Katsanos, Joseph L. Mills, et al. "Performance of Prognostic Markers in the Prediction of Wound Healing or Amputation Among Patients with Foot Ulcers in Diabetes: A Systematic Review." *Diabetes/Metabolism Research Reviews*, 2016.

Raffaele Grande, Giulia Fiori, G. Russo, P. Fioramonti, M. Campagnol, and L. Di Marzo. "A Multistage Combined Approach to Promote Diabetic Wound Healing in COVID-19 Era." *International Wound Journal*, 2020.

Ridho Sinaga, Djony E. Tjandra, Richard Sumangkut, B. Karundeng, and F. F. Langi. "PEDIS Score Analysis in Diabetic Foot Ulcer Following Angioplasty Revascularization Procedure," 2021.

Riyad Karmy-Jones, Beejay Feliciano, Desarom Teso, Jill Sommerset, Yolanda Vea, and Mathew Dally. "The Utility of Advanced Lower-Extremity Duplex Using Pedal Acceleration Time in the Management of the Threatened Diabetic Foot." *Journal of the American Podiatric Medical Association (Print)*, 2024.

Rona Kartika, I. Alwi, F. Suyatna, E. Yunir, S. Waspadji, S. Immanuel, T. Silalahi, et al. "The Use of Image Processing in the Evaluation of Diabetic Foot Ulcer Granulation After Treatment with Advanced-Platelet Rich Fibrin + Hyaluronic Acid," 2020.

Rongzhi Wen, Xin-Hua Cheng, Hong Cao, Lei Zhang, Fangcheng Luo, and Wei Shang. "Transverse Tibial Bone Transfer in the Treatment of Diabetes Foot Ulcer: A Pilot Study." *Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy*, 2023.

Rushabh A Parekh, V. Athavale, and Saili Kelshikar. “The Value of Pressure Indexes in Predicting the Outcome of Diabetic Foot Ulcers as a Guide to Further Management.” *Cureus*, 2024.

S. Brown, H. Collier, Lucy Askew, Rachael Gilberts, L. Sharples, Jane Nixon, Elizabeth McGinnis, et al. “Diabetic Foot Ulcer Photography Study: A Study Within a Trial to Assess the Reliability of Two-Dimensional (2D) Photography for the Assessment of Ulcer Healing in Patients with Diabetes-Related Foot Ulcers—Protocol Paper.” *BMJ Open*, 2025.

S. Engberg, K. Kirketerp-Møller, H. Ullits Andersen, and A. Rasmussen. “Incidence and Predictors of Recurrent and Other New Diabetic Foot Ulcers: A Retrospective Cohort Study.” *Diabetic Medicine*, 2019.

S. H. Lu, and Ann-Marie McLaren. “Wound Healing Outcomes in a Diabetic Foot Ulcer Outpatient Clinic at an Acute Care Hospital: A Retrospective Study.” *Journal of Wound Care*, 2017.

S. Jacqueminet, A. Hartemann-Heurtier, R. Izzillo, Philippe Cluzel, JL Golmard, G. H. Van, F. Koskas, and André Grimaldi. “Percutaneous Transluminal Angioplasty in Severe Diabetic Foot Ischemia: Outcomes and Prognostic Factors.” *Diabetes & Metabolism*, 2005.

S. Mehta, Eric A. Breitbart, W. Berberian, Frank A. Liporace, and Sheldon S. Lin. “Bone and Wound Healing in the Diabetic Patient.” *Foot and Ankle Clinics*, 2010.

S. Spiliopoulos, Magdalini Georgiadou, Anastasia Karahaliou, S. Grigoriadis, K. Palialexis, L. Reppas, and E. Brountzos. “Feasibility and Clinical Value of Intraprocedural Doppler Ultrasonography Blood Flow Parameters During Peripheral Endovascular Procedures for Limb Salvage: A Pilot Study.” *Journal of Endovascular Therapy*, 2023.

S. Zimny, and M. Pfohl. “Healing Times and Prediction of Wound Healing in Neuropathic Diabetic Foot Ulcers: A Prospective Study.” *Experimental and Clinical Endocrinology & Diabetes*, 2005.

Scott J Edwards, Jingting Yao, Marcos C. Schechter, M. Fayfman, G. Santamarina, T. Feiweier, Gerardo Blanco, et al. “Feasibility of Multiparametric Perfusion Assessment in Diabetic Foot Ulcer

Using Intravoxel Incoherent Motion and Blood Oxygenation-Level Dependent MRI.” *Journal of Magnetic Resonance Imaging*, 2023.

Sebastián Flores-Escobar, Y. García-Álvarez, F. Álvaro-Afonso, M. López-Moral, M. García-Madrid, and J. Lázaro-Martínez. “Clinical Effects of Weekly and Biweekly Low-Frequency Ultrasound Debridement Versus Standard of Wound Care in Patients with Diabetic Foot Ulcers: A Pilot Randomized Clinical Trial.” *International Journal of Lower Extremity Wounds*, 2025.

Seoyoung C. Kim, Junhyung Kim, Jaehoon Choi, Woonhyeok Jeong, and Sunyoung Kwon. “Polydeoxyribonucleotide Improves Peripheral Tissue Oxygenation and Accelerates Angiogenesis in Diabetic Foot Ulcers.” *Archives of Plastic Surgery*, 2017.

Shiping Ji, Xinhuang Hou, Xunliang Zhang, Zhiye Wu, Jie Lin, Yichen Lin, Jie Wu, et al. “The Relationship Between the Global Limb Anatomic Staging System Inframalleolar Modifier and the Outcomes of Diabetic Foot Ulcer with Peripheral Artery Disease.” *Annals of Vascular Surgery*, 2022.

Sichun Zhao, Fudie Guo, Yonghui Zang, Rong Hu, Xianjun Yu, Hongmei Zhang, Tingting Xie, et al. “The Association of the Perioperative Neutrophil-to-Lymphocyte Ratio with Wound Healing in Patients with Wagner Grade 3 and 4 Diabetic Foot Ulcers After Tibial Cortex Transverse Transport Surgery: A Prospective Observational Cohort Study.” *Frontiers in Endocrinology*, 2024.

Sijie Yang, Kaixiang Pan, Qikai Hua, Hongjie Su, Jun Hou, Kaibing Liu, and Jinming Zhao. “Correlation Analysis of Patients with Diabetic Foot Ulcers Treated with Tibial Cortex Transverse Transport Surgery and Platelet-to-Lymphocyte Ratio and Monocyte-to-Neutrophil Ratio.” *Advances in Clinical and Experimental Medicine*, 2024.

Sofija Pejškova, Gordana Georgieva, Savetka Paljoskovska Jordanova, Stefania Azmanova Mladenovska, Katerina Jovanovska, Blagoja Srbov, and Sofija Tusheva. “Dellon Decompression of the Tarsal Tunnel: An Effective Approach to Improving Blood Flow, Promoting Ulcer Healing and

Recovery of Sensibility in Diabetic Patients.” *Journal of Plastic, Reconstructive & Aesthetic Surgery*, 2025.

Sooraj M Shah, A. Bortnick, O. Bertrand, O. Costerousse, W. Htun, and T. Kwan. “Transpedal Vs. Femoral Access for Peripheral Arterial Interventions—A Single Center Experience.” *Catheterization and Cardiovascular Interventions*, 2019.

Stephanie Mae Macfarlane, Sarina Xinyan Zhao, Jane Olivia Lafrenz, Manisha Vanya Nagaratnam, Adrian Tchen, Clare Elizabeth Linton, and Lili Yuen. “Effect of a Multidisciplinary Team Approach on the Management of Diabetic Foot Ulcers on the Central Coast: A Review of the Gosford Hospital High-Risk Foot Clinic.” *International Wound Journal*, 2024.

Stephanie P. Hao, J. Houck, Olivia V. Waldman, J. Baumhauer, and I. Oh. “Prediction of Post-Interventional Physical Function in Diabetic Foot Ulcer Patients Using Patient Reported Outcome Measurement Information System (PROMIS).” *Foot and Ankle Surgery*, 2020.

T. Elgzyri, J. Larsson, Johan Thörne, Karl-Fredrik Eriksson, and Jan Apelqvist. “Outcome of Ischemic Foot Ulcer in Diabetic Patients Who Had No Invasive Vascular Intervention.” *European Journal of Vascular and Endovascular Surgery*, 2013.

T. Elgzyri, J. Larsson, Per Nyberg, Johan Thörne, Karl-Fredrik Eriksson, and Jan Apelqvist. “Early Revascularization After Admittance to a Diabetic Foot Center Affects the Healing Probability of Ischemic Foot Ulcer in Patients with Diabetes.” *European Journal of Vascular and Endovascular Surgery*, 2014.

T. Kwan, Sooraj M Shah, N. Amoroso, R. Diwan, P. Makker, J. Ratcliffe, M. Lala, et al. “Feasibility and Safety of Routine Transpedal Arterial Access for Treatment of Peripheral Artery Disease.” *The Journal of Invasive Cardiology*, 2015.

T. Macioch, E. Sobol, B. Mrozikiewicz-Rakowska, A. Krakowiecki, and T. Hermanowski. "Health Related Quality of Life In Patients With Diabetic Foot Ulceration - Observational Study In Poland." *Value in Health*, 2015.

T. Nakama, N. Watanabe, T. Haraguchi, H. Sakamoto, D. Kamoi, Y. Tsubakimoto, K. Ogata, et al. "Clinical Outcomes of Pedal Artery Angioplasty for Patients With Ischemic Wounds: Results From the Multicenter RENDEZVOUS Registry." *JACC: Cardiovascular Interventions*, 2017.

Takeshi Fukuda, D. Hughes, and M. Schweitzer. "Value of MRI in Changing of Diabetic Foot Osteomyelitis Management." *Journal of Magnetic Resonance Imaging*, 2019.

Tawfik Abo Mera. "Role of APSV in Predicting Healing of Diabetic Foot Lesions," 2019.

Thomas Collins, Daniel Hickman, Danuksha K Amarasena, and Anand Pillai. "Pedal Medial Artery Calcification Score as a Prognostic Marker for the Success of Surgical Intervention in Diabetic Foot Disease." *Practical Diabetes*, 2024.

Tracy J. Cheun, Joseph P. Hart, and Mark G. Davies. "Concomitant Pedal Interventions Improve Outcomes for Tibial Interventions in Chronic Limb-Threatening Ischemia." *Annals of Vascular Surgery*, 2024.

Tze-Woei Tan, D. Armstrong, C. Chong, Nicholas J. HAMILTON-COTTER, Onkar Kshirsagar, D. Marrero, and D. Cotter. "125-OR: Association Between Preventive Podiatric Care and Outcomes of New Diabetic Foot Ulceration Among Patients with End Stage Renal Disease." *Diabetes*, 2022.

V. Alexandrescu, G. Hubermont, Y. Philips, B. Guillaumie, C. Ngongang, V. Coessens, P. Vandebossche, M. Coulon, G. Ledent, and J.-C. Donnay. "Combined Primary Subintimal and Endoluminal Angioplasty for Ischaemic Inferior-Limb Ulcers in Diabetic Patients: 5-Year Practice in a Multidisciplinary 'Diabetic-Foot' Service." *European Journal of Vascular and Endovascular Surgery*, 2009.

V. Alexandrescu, Sophie Brochier, A. Limgba, S. Balthazar, Hafid Khelifa, Pierrick De Vreese, K. Azdad, et al. "Healing of Diabetic Neuroischemic Foot Wounds With Vs Without Wound-Targeted Revascularization: Preliminary Observations From an 8-Year Prospective Dual-Center Registry." *Journal of Endovascular Therapy*, 2019.

V. Chuter, N. Schaper, J. Mills, R. Hinchliffe, D. Russell, N. Azuma, C. Behrendt, et al. "Effectiveness of Revascularisation for the Ulcerated Foot in Patients with Diabetes and Peripheral Artery Disease: A Systematic Review." *Diabetes/Metabolism Research Reviews*, 2023.

V. Chuter, N. Schaper, R. Hinchliffe, J. Mills, N. Azuma, C. Behrendt, E. Boyko, et al. "Performance of Non-invasive Bedside Vascular Testing in the Prediction of Wound Healing or Amputation Among People with Foot Ulcers in Diabetes: A Systematic Review." *Diabetes/Metabolism Research Reviews*, 2023.

V. E. Parks, P. Crisologo, L. Lavery, Jaminelli L Banks, Michael D. Liette, and Lance A. Johnson. "39-LB: Progress in Diabetic Foot Ulcer Healing with Standard of Care Therapy Alone: A Meta-Analysis," 2020.

V. Venkatesan, and Jayakumar Rangasamy. "Diabetic Pedal Osteomyelitis and Its Treatment." *Chonnam Medical Journal*, 2023.

Vishnu S. Ravidas, Samadarsi P., and A. G. "Prospective Observational Study Evaluating the Predictive Value of Ankle Branchial Pressure Index on the Outcomes of Diabetic Foot Ulcers." *International Surgery Journal*, 2020.

W. Bevan, and M. Tomlinson. "Radiographic Measures as a Predictor of Ulcer Formation in Diabetic Charcot Midfoot." *Foot & Ankle International*, 2008.

Yan Chen, Xiaocong Kuang, Jia Zhou, Puxiang Zhen, Zi-san Zeng, Zhenxun Lin, Wei Gao, et al. "Proximal Tibial Cortex Transverse Distraction Facilitating Healing and Limb Salvage in Severe and Recalcitrant Diabetic Foot Ulcers." *Clinical Orthopaedics and Related Research*, 2019.

Yan Mi, and Jing Wang. “Effectiveness of Personalized Continuous Care in Wound Care of Patients with Diabetic Foot Ulcers.” *Frontiers in Endocrinology*, 2025.

Yan-Bin Wang, Yan Lv, Guang-Yu Li, Ji-Ting Zheng, Qing-Xin Jiang, and Ran Wei. “Clinical Comprehensive Treatment Protocol for Managing Diabetic Foot Ulcers: A Retrospective Cohort Study.” *World Journal of Clinical Cases*, 2024.

Yingzhou Liu, Menggang Yu, Jamie N LaMantia, Jennifer Mason Lobo, J. Boutilier, Yao Liu, and Meghan B Brennan. “Associations Between Specialty Care and Improved Outcomes Among Patients with Diabetic Foot Ulcers.” *PLoS ONE*, 2023.

Yumika Nishio, Y. Tsuji, I. Kitano, and H. Terashi. “Influence of Peripheral Arterial Disease on Wound Healing in Heel Pressure Ulcers.” *The Kobe Journal of Medical Sciences*, 2022.

Максим Борисович Горобейко. “Effectiveness of Different Approaches to Local Treatment in Diabetic Foot Syndrome Patients with Regard to Ischemia of Lower Extremities,” 2014.